transmiss
gastroenter
coronaviru
tgev
envelop
viru
intern
core
made
rna
n
protein
presenc
protein
purifi
core
unexpect
sinc
integr
membran
protein
work
demonstr
signific
proport
protein
integr
within
viru
membran
interact
core
ionic
interact
purifi
core
treat
collect
caiotrop
agent
remov
protein
correl
destabil
structur
core
structur
core
stabil
presenc
dival
cation
high
ph
partial
resist
nonion
deterg
reduc
agent
demonstr
interact
protein
core
specif
mediat
carboxyterminu
base
three
type
evid
interact
domain
map
residu
locat
carboxyterminu
vitro
bind
assay
protein
mutant
purifi
nucleocapsid
ii
presenc
interact
domain
carboxyterminu
confirm
inhibit
bind
use
synthet
peptid
mimick
bind
domain
iii
bind
protein
nucleocapsid
inhibit
mspecif
mab
direct
cterminu
protein
data
consolid
structur
composit
tgev
intern
core
inflammatori
diseas
human
tcell
leukaemia
viru
typel
associ
myelopathi
ham
tsp
occur
htlvl
infect
individu
associ
high
htlvi
proviru
load
hypothesis
risk
develop
hamtsp
depend
upon
effici
immun
respons
viru
may
differ
individu
polymorph
gene
influenc
respons
casecontrol
associ
studi
previous
demonstr
possess
hlaa
associ
lower
risk
hamtsp
lower
proviru
load
healthi
carrier
hc
htlvl
howev
hlaa
account
observ
differ
risk
hamtsp
addit
hlatyp
show
hlacw
also
associ
diseas
protect
lower
provir
load
hc
contrast
hlab
associ
higher
suscept
hamtsp
p
higher
proviru
load
hamtsp
patient
suggest
associ
hlab
suscept
hamtsp
like
due
proinflammatori
gene
linkag
disequilibrium
b
addit
individu
heterozyg
three
hla
loci
lower
htlvi
proviru
load
homozyg
one
loci
result
consist
propos
strong
classirestrict
cytotox
cell
ctl
respons
reduc
provir
load
henc
risk
diseas
kj
jefferi
et
al
proc
natl
acad
sci
usa
background
hepat
c
viru
hcv
specif
cytotox
lymphocyt
ctl
thought
involv
viral
pathogenesi
design
mhc
tetram
base
epitop
protein
cvngvcwtv
klvalginav
directli
quantifi
hcvspecif
ctl
pna
aimsmethod
analys
effect
hcvspecif
ctl
diseas
cours
patient
acut
infect
aminoacid
sequenc
viral
epitop
chronic
infect
patient
result
patient
acut
infect
ctl
respons
detect
much
higher
level
chronic
infect
associ
clearanc
viru
resolut
diseas
twentytwo
chronicallyinfect
patient
detect
hcvspecif
ctl
tetram
aminoacid
variat
detect
viral
code
sequenc
epitop
major
variat
genotyperel
differ
patient
potenti
viral
ctil
escap
mutant
identifi
anchor
residu
epitop
infect
viru
conserv
conclus
find
suggest
hcvspecif
cell
one
factor
play
role
restrain
elimin
hcv
although
ctl
escap
may
occur
hcv
infect
seem
common
event
fabienn
mackay
garvan
fiona
minn
moira
bruce
neil
mabbott
insitut
medic
research
darlinghurst
nsw
australia
institut
anim
health
ogston
build
west
main
road
edinburgh
uk
creutzfeldtjakob
diseas
cjd
human
sheep
scrapi
bovin
spongiform
encephalopathi
member
group
neurolog
diseas
known
transmiss
spongiform
encephalopathi
tse
prion
diseas
natur
tse
infect
usual
acquir
peripher
exposur
exampl
ingest
transplant
contamin
tissu
experiment
peripher
exposur
tse
agent
usual
accumul
lymphoid
tissu
long
infect
detect
central
nervou
system
studi
mous
scrapi
model
shown
matur
follicular
dendrit
cell
fdc
express
prion
protein
prp
critic
replic
lymphoid
tissu
absenc
neuroinvas
impair
fdc
requir
lymphotoxin
alphabeta
signal
bcell
maintain
differenti
state
block
signal
lymphotoxin
betareceptorimmunoglobulin
fusion
protein
temporarili
inactiv
fdc
within
hour
approxim
day
observ
lead
predict
treatment
interfer
integr
function
fdc
also
interfer
tse
pathogenesi
demonstr
temporari
inactiv
fdc
treatment
ltbrig
block
scrapi
replic
lymphoid
tissu
delay
neuroinvas
result
suggest
new
potenti
approach
prophylaxi
tse
impair
antigen
present
hivspecif
lymphocyt
regul
mhc
class
human
dendrit
cell
muriel
andrieu
dorin
chassin
desoutt
isabel
bouchaert
marjori
baillet
daniel
hanau
guillet
ann
hosmalin
laboratoir
dimmunologi
de
patholog
infectieus
et
tumoral
pari
franc
servic
commun
de
icgm
rue
du
fauborg
st
jacqu
pari
franc
inserm
ep
biologi
de
cellul
dendritiqu
humain
etabliss
du
sangalsac
strasbourg
franc
earli
regulatori
nef
protein
involv
impair
immun
respons
downregul
surfac
express
major
histocompat
class
molecul
differ
immort
cell
line
lymphocyt
thu
decreas
lysi
cytotox
cell
induct
primari
immun
respons
requir
dendrit
cell
dc
express
dcsign
major
candid
first
cell
intern
viru
present
cell
mucos
contamin
test
whether
nef
impair
mhci
restrict
antigen
present
dendrit
cell
use
recombin
vaccinia
virus
induc
express
nef
control
protein
human
monocytederiv
dendrit
cell
flow
cytometr
analysi
doubl
label
vaccinia
protein
major
histocompat
class
show
lai
nef
inde
downregul
mhc
class
surfac
express
dendrit
cell
major
histocompat
class
irestrict
present
nefspecif
cell
clone
infect
patient
decreas
interferong
elispot
assay
present
revers
transcriptas
epitop
peptid
sort
nefinfect
cell
decreas
peptideconcentr
depend
way
confirm
role
mhc
downregul
impair
specif
respons
therefor
nef
downregul
major
histocompat
class
express
dendrit
cell
impair
present
hivspecif
cell
action
nef
probabl
induc
deleteri
delay
earli
respons
first
day
infect
onset
new
viral
mutant
trigger
sever
therapeut
option
strong
impair
stimulatori
function
monocytederiv
dendrit
cell
found
chronic
carrier
hepat
c
viru
long
term
respond
therapi
christin
bain
mechan
underli
progress
chronic
carrier
state
follow
hcv
infect
well
understood
dendrit
cell
dc
profession
antigen
present
cell
requir
initi
primari
immun
respons
also
involv
mani
viral
infect
establish
viral
persist
report
vitro
monocytederiv
dc
chronic
carrier
harbor
hcv
genom
sequenc
differ
stage
matur
dc
dc
cultur
sequenc
uniqu
natur
distinct
identifi
patient
serum
liver
biopsi
peripher
blood
mononuclear
cell
select
within
hypervari
region
also
within
regulatori
domain
import
express
viral
protein
immatur
matur
stage
dc
display
normal
morpholog
phenotyp
express
molecul
import
antigen
present
ie
mhc
antigen
costimulatori
molecul
capac
immatur
dc
captur
antigen
via
mannos
receptor
compar
dc
deriv
naiv
individu
howev
abil
matur
stage
stimul
prolifer
allogen
cell
dramat
impair
comparison
dc
nafv
control
p
activ
immunosuppress
mechan
exclud
sinc
dc
deriv
chronic
patient
exert
activ
inhibitori
effect
allogen
mlr
induc
dc
seroneg
individu
could
neither
show
dysregul
product
stimul
dc
deriv
chronic
patient
lipopolysaccharid
compar
normal
individu
howev
allostimulatori
function
dc
deriv
hcv
patient
clearli
correl
diseas
state
sinc
function
restor
long
term
respond
antivir
therapi
pb
overal
result
suggest
independ
viral
load
infect
genotyp
natur
infect
hcv
monocytederiv
dc
appear
constitut
extrahepat
reservoir
specif
hcv
variant
impair
antigen
present
cell
apc
function
could
play
critic
role
develop
viral
persist
vivo
function
mucos
immun
respons
mediat
iga
pia
skott
marieth
ehnlund
erik
lucht
joakim
dillner
ewa
bjo
rling
microbiolog
tumorbiolog
center
karolinska
institut
theorel
vag
stockholm
sweden
research
center
south
hospit
karolinska
institut
stockholm
sweden
depart
infecti
diseas
hudding
univers
hospit
sweden
human
immunodefici
viru
hiv
infect
transmit
predominantli
sexual
intercours
transmiss
requir
dissemin
viru
site
infect
mucos
surfac
cell
zone
secondari
lymphoid
organ
mucos
transmiss
number
barrier
need
pass
infect
dissemin
blood
first
barrier
epithelia
surfac
viral
adhes
occur
may
prevent
siga
igg
antibodi
hiv
envelop
glycoprotein
gp
studi
investig
vitro
function
capac
specif
immun
respons
saliva
comparison
immun
respons
serum
natur
infect
affin
chromatographi
purifi
antibodi
igg
iga
isotyp
pairwis
sequenti
saliva
serum
sampl
variat
differ
posit
individu
consider
high
suggest
patient
broad
spectra
siga
specif
other
express
specif
siga
mediat
respons
purifi
iga
antibodi
use
vitro
neutral
assay
infect
tcell
adapt
strain
tcla
primari
isol
tcla
syncyti
induc
si
nonsyncyti
induc
nsi
phenotyp
igamedi
neutral
record
studi
tcla
strain
test
primari
isol
great
interindividu
varianc
neutral
capac
observ
indic
presenc
potent
iga
antibodi
gener
phenomenon
observ
individu
basi
even
late
stage
diseas
lack
vitro
replic
system
small
anim
model
hinder
discoveri
novel
therapi
hcv
howev
recent
molecular
characteris
gbvb
close
relat
flaviviru
isol
infect
tamarin
sanguinu
sp
open
new
opportun
studi
hcv
diseas
use
gbvb
surrog
viru
gbvb
classifi
viru
famili
hcv
studi
describ
infect
four
redbelli
tamarin
sanguinu
labiatu
gbvb
infecti
sera
characteris
diseas
monitor
viral
liver
enzym
level
serum
one
anim
cull
day
post
infect
sera
use
infecti
stock
titr
e
genom
equival
per
ml
geml
remain
anim
monitor
day
pi
anim
show
viral
load
e
e
geml
day
pi
level
maintain
day
two
three
infect
tamarin
show
rais
level
alt
gldh
day
pi
anim
clear
viru
day
pi
antigbvb
antibodi
remain
anim
maintain
normal
liver
enzym
level
throughout
infect
high
level
viral
rna
serum
day
pi
antigbvb
antibodi
detect
serum
anim
liver
infect
tamarin
show
evid
hepat
periport
lymphocyt
infiltr
qualit
increas
collagen
deposit
around
portal
tract
typic
earli
stage
fibrosi
work
ongo
valid
model
engin
coronaviru
rna
genom
infecti
bacteri
artifici
chromosom
lui
enjuan
fernando
almazan
jose
gonzalez
zoltan
penz
ander
izeta
enriqu
calvo
juan
planaduran
centro
nacion
de
biotecnologia
csic
depart
molecular
cell
biolog
campu
universidad
autonoma
madrid
spain
fort
dodg
veterinaria
olot
spain
construct
cdna
clone
encod
larg
size
rna
molecul
biolog
interest
like
coronaviru
genom
among
largest
matur
rna
molecul
known
biolog
hamper
instabl
cdna
bacteria
shown
applic
two
strategi
clone
cdna
bacteri
artifici
chromosom
bac
nuclear
express
rna
typic
produc
within
cytoplasm
use
engin
larg
rna
molecul
cdna
encod
infecti
coronaviru
rna
genom
clone
bac
rescu
coronaviru
conserv
genet
marker
introduc
throughout
sequenc
show
standard
mrna
pattern
antigen
characterist
expect
synthet
viru
cdna
transcrib
within
nucleu
rna
transloc
cytoplasm
interestingli
recov
viru
essenti
sequenc
origin
one
splice
observ
cdna
deriv
attenu
isol
exclus
replic
respiratori
tract
swine
engin
infecti
cdna
spike
gene
viru
replac
gene
enter
isol
synthet
viru
replic
abundantli
enter
tract
fulli
virul
demonstr
tropism
virul
recov
coronaviru
gan
modifi
open
possibl
employ
infecti
cdna
vector
vaccin
develop
human
porcin
canin
felin
speci
suscept
group
coronavirus
fact
tgev
cdna
success
use
express
larg
amount
cell
green
fluoresc
protein
recognit
rna
encapsid
signal
yeast
la
doublestrand
rna
viru
tsutomu
fujimura
rosa
esteban
inst
csicuniv
salamanca
edificio
deparament
avda
del
campo
charro
sn
salamanca
spain
yeast
la
viru
linear
dsrna
genom
two
open
read
frame
orf
gag
encod
major
coat
protein
orf
pol
encod
rnadepend
rna
polymeras
express
gagpol
fusion
protein
ribosom
frameshift
mechan
pol
region
fusion
protein
singlestrand
bind
activ
respons
encapsid
viral
rna
encapsid
signal
la
contain
nucleotid
stemloop
bulg
side
stem
open
empti
particl
specif
bind
encapsid
signal
vitro
found
bind
empti
particl
protect
bulg
surround
two
nucleotid
cleavag
fe
ii
edtagener
hydroxyl
radic
interestingli
loop
sequenc
protect
howev
rnaseprotect
vitro
mutagenesi
experi
indic
loop
essenti
bind
although
sequenc
four
nucleotid
loop
essenti
data
rnaseprotect
chemic
modif
experi
suggest
base
c
also
directli
involv
bind
empti
particl
rather
indirectli
potenti
basepair
g
result
therefor
suggest
pol
domain
fusion
protein
contact
encapsid
signal
two
site
one
bulg
g
c
base
open
loop
two
site
conserv
encapsid
signal
satellit
rna
la
viru
rna
bind
properti
bunyamwera
viru
nucleocapsid
protein
jane
osborn
richard
elliott
institut
virolog
univers
glasgow
church
street
glascow
uk
genom
bunyamwera
bun
viru
famili
bunyavirida
genu
bunyaviru
compris
three
negativesens
rna
segment
act
transcript
templat
viral
polymeras
encapsid
nucleocapsid
protein
n
previou
studi
suggest
encapsid
signal
may
resid
within
terminu
segment
bun
n
protein
express
tag
fusion
protein
e
coli
purifi
metal
chelat
chromatographi
rna
probe
contain
termin
termin
base
bun
small
genom
segment
use
investig
bind
n
protein
vitro
use
gel
mobil
shift
filterbind
assay
acrylamid
gel
number
discret
rnan
complex
resolv
analysi
filter
bind
data
indic
degre
cooper
n
protein
bind
rnan
complex
resist
digest
mgml
rnase
competit
assay
varieti
viral
nonvir
rna
identifi
region
within
terminu
bun
segment
n
high
prefer
bind
site
may
constitut
signal
initi
encapsid
n
intracellular
retrotransposit
exogen
primat
retroviru
axel
rethwilm
martin
heinkelein
technisch
universitaet
dresd
institut
fuer
virologi
gerichtsstr
dresden
germani
foami
viru
fv
subgroup
retrovirida
revers
transcrib
rna
pre
genom
late
replic
cycl
leav
infect
cell
studi
whether
marker
genetransduc
fv
vector
abl
reshuttl
nucleu
integr
host
cell
genom
dna
potenti
intracellular
retrotransposit
vector
deriv
retrovirus
detect
limit
assay
found
cell
transfect
fv
vector
stabli
transduc
harbour
vector
integr
gener
integr
depend
express
function
capsid
revers
transcriptas
integras
protein
involv
extracellular
step
pcr
analysi
region
long
termin
repeat
determin
provir
integr
site
show
revers
transcript
step
taken
place
gener
integr
coexpress
mutat
envelop
allow
particl
egress
avoid
extracellular
infect
result
significantli
increas
rescu
cell
harbour
integr
suggest
accumul
provirus
via
intracellular
retrotransposit
integr
strategi
fv
replic
respons
footandmouth
diseas
viru
increas
mutagenesi
influenc
viral
load
fit
loss
infect
saleta
sierra
n
merced
pedro
lowenstein
esteban
domingo
passag
footandmouth
diseas
viru
fmdv
cell
cultur
presenc
mutagen
base
analog
result
decreas
infect
occasion
extinct
viru
mutagen
treatment
led
increas
mutat
frequenc
highest
increas
observ
correspond
polymeras
code
region
remain
conserv
nonmutagen
fmdv
popul
mutant
spectrum
heterogen
region
becam
similar
variabl
mutagen
popul
popul
passag
parallel
absenc
mutagen
low
viral
fit
enhanc
frequenc
extinct
presenc
mutagen
shown
close
relat
fmdv
clone
differ
fold
rel
fit
passag
low
multipl
infect
increas
frequenc
extinct
larg
viral
load
allow
extinct
mutagenesi
low
fit
virus
result
suggest
strategi
combin
reduct
viral
load
viral
fit
increas
mutagenesi
could
effect
potenti
antivir
strategi
follicular
dendrit
cell
support
replic
strain
scrapi
karen
brown
dian
l
ritchi
moira
e
bruce
institut
anim
health
neuropathogenesi
unit
ogston
build
west
main
road
edinburgh
uk
immun
system
central
pathogenesi
scrapi
transmiss
spongiform
encephalopathi
infect
peripher
rout
tse
agent
replic
spleen
lymph
node
neuroinvas
characteris
cell
support
replic
tissu
import
understand
earli
pathogenesi
may
indic
potenti
target
therapi
host
protein
prp
requir
tse
agent
replic
accumul
modifi
form
infect
tissu
abnorm
prp
detect
follicular
dendrit
cell
lymphoid
tissu
mice
experiment
infect
scrapi
sheep
natur
scrapi
human
newvari
creutzfeldtjakob
diseas
cjd
previou
studi
use
ionis
radiat
sever
combin
immunodefici
mice
scid
produc
strong
evid
involv
fdc
scrapi
replic
clarifi
role
fdc
produc
chimaer
mice
mismatch
prp
statu
fdc
cell
immun
system
graft
prp
prpbone
marrow
prpprpor
scid
prpprpmice
use
model
obtain
strong
evid
replic
strain
scrapi
depend
prpexpress
fdc
confoc
analysi
spleen
scidchimaer
mice
demonstr
colocalis
prp
fdc
recipi
bone
marrow
graft
carri
function
prp
gene
suggest
fdc
bonemarrow
deriv
produc
prp
protein
mcbride
pa
et
al
prp
protein
associ
follicular
dendrit
cell
spleen
lymph
node
uninfect
scrapi
infect
mice
journal
patholog
fraser
h
farquhar
cf
ionis
radiat
influenc
scrapi
incub
period
mice
veterinari
microbiolog
brown
kl
et
al
scrapi
replic
lymphoid
tissu
depend
prion
protein
express
follicular
dendrit
cell
natur
medicin
previous
report
discoveri
novel
retrovir
sequenc
human
tissu
sequenc
endogen
human
genom
appear
repres
novel
infecti
human
retroviru
provision
design
human
preliminari
studi
suggest
might
common
infect
human
extrem
low
viral
load
griffith
et
al
j
virol
recent
shown
load
increas
patient
arthriti
system
lupu
erythematosu
use
nest
pcr
assay
dna
detect
synovi
membran
biopsi
patient
arthriti
peripher
blood
sampl
patient
arthriti
lupu
also
posit
viru
contrast
detect
rare
normal
tissu
inflammatori
condit
griffith
et
al
arthriti
rheum
current
work
focus
develop
viru
cultur
system
develop
serolog
assay
infect
recent
data
present
herpesvirus
human
cytomegaloviru
hcmv
establish
persist
infect
within
host
develop
differ
mechan
escap
host
immun
defenc
analyz
whether
antigen
present
mediat
dendrit
cell
dc
disrupt
hcmv
infect
first
analyz
whether
dc
permiss
hcmv
dc
gener
monocyt
presenc
gmcsf
infect
endotheli
cell
ecv
human
foreskin
fibroblastadapt
ffv
clinic
isol
increas
viral
dna
measur
quantit
real
time
taqman
pcr
ecvinfect
dc
immedi
earli
ie
protein
found
ffvinfect
dc
doubl
immunofluoresc
wherea
ie
well
matrix
protein
detect
ecvinfect
dc
data
show
dc
fulli
permiss
ecadapt
hcmv
strain
wherea
hcmv
infect
ffv
abrog
level
ie
gene
express
furthermor
could
show
hcmv
infect
dc
downregul
mhc
class
molecul
well
cosign
thu
lead
impair
cell
respons
antigen
present
document
suppress
allogen
mix
lymphocyt
reaction
mlr
conclus
could
show
hcmv
develop
mechan
impair
initi
immun
respons
virus
exploit
differ
strategi
escap
immun
surveil
includ
introduct
mutat
cytotox
lymphocyt
ctl
epitop
sequenc
epitop
critic
bind
mhc
classi
molecul
recognit
specif
cti
interact
may
lost
mutat
sequenc
analysi
nucleoprotein
gene
influenza
virus
isol
netherland
reveal
two
independ
amino
acid
mutat
anchor
residu
specif
ctl
epitop
srywairtr
mutat
found
influenza
virus
isol
influenza
season
subsequ
season
influenza
season
novel
mutat
ctl
epitop
posit
introduc
mutat
prove
conserv
influenza
virus
isol
onward
mutat
abrog
mhc
classi
present
allow
escap
recognit
specif
cti
multimer
humanis
antivaricella
zoster
viru
vzv
antibodi
fragment
neutralis
vzv
andi
porter
pd
drew
moss
c
grose
k
duu
c
hatfield
wj
harri
univers
aberdeen
depart
molecular
cell
biolog
institut
medic
scienc
foresterhil
aberdeen
uk
univers
iowa
depart
microbiolog
iowa
citi
ia
usa
viral
coat
glycoprotein
site
attach
fusion
varicellazost
viru
vzv
host
cell
import
cell
cell
spread
murin
monoclon
antibodi
mab
bind
glycoprotein
h
neutralis
vzv
vitro
absenc
complement
inhibit
cell
cell
spread
vzv
cultur
cell
humanis
antibodi
gener
mab
complementar
determin
region
graft
mab
retain
bind
vitro
neutralis
activ
crossreact
ten
clinic
isol
biolog
activ
humanis
antibodi
around
time
standard
varicellazost
immunoglobulin
vzig
prepar
mg
mg
basi
shingl
treatment
topic
deliveri
antibodi
may
prefer
penetr
neural
tissu
end
singlechain
antibodi
fragment
scab
produc
escherichia
coli
antibodi
fragment
retain
bind
properti
whole
antibodi
howev
monomer
scab
exhibit
significantli
reduc
neutralis
activ
compar
bival
mab
neutralis
activ
scab
could
enhanc
inclus
secondari
antibodi
specif
human
constant
kappa
chain
scab
shorten
peptid
linker
join
vh
vk
domain
even
residu
encourag
multimeris
diabodi
neutralis
efficaci
closer
parent
monoclon
result
may
explain
need
viral
receptor
crosslink
neutralis
antibodi
must
suffici
size
steric
inhibit
fusion
process
splice
ctype
lectinlik
gene
encod
rat
cytomegaloviru
sebastian
voigt
gordon
r
sandford
william
h
burn
medic
colleg
wisconsin
watertown
plank
road
milwauke
wi
usa
found
first
ctype
lectinlik
homologu
herpesvirus
interestingli
gene
english
strain
rat
cytomegaloviru
rcmv
splice
five
exon
show
splice
pattern
exon
boundari
similar
human
differenti
antigen
genom
sequenc
analysi
clone
kpn
r
rcmv
blast
programm
reveal
signific
homolog
sever
ctype
lectincontain
molecul
implic
natur
killer
nk
cell
interact
well
gene
four
poxvirus
unclassifi
african
swine
fever
viru
cap
site
gene
map
race
primer
extens
experi
splice
pattern
confirm
core
promotor
rcmv
lectinlik
gene
contain
gata
rather
tata
box
also
unusu
translat
protein
seem
initi
methionin
sinc
none
open
read
frame
gene
express
delay
earli
late
phase
viral
replic
cycl
cell
transient
transfect
kpn
rflag
fusion
plasmid
stain
posit
upon
indirect
detect
flag
fitcconjug
antibodi
wherea
controltransfect
cell
indic
express
protein
western
blot
analysi
show
protein
kda
diminish
kda
glycosyl
inhibit
studi
role
viru
replic
pathogenesi
recombin
viru
construct
gene
interrupt
vivo
experi
way
background
method
although
assum
viremia
chickenpox
peak
around
onset
skin
rash
never
fulli
document
due
lack
quantit
assay
use
intern
control
quantit
pcr
assay
target
gene
j
clin
microbiol
press
measur
vzv
dna
level
singl
plasma
serum
whole
blood
specimen
obtain
within
day
prior
day
onset
rash
untreat
immunocompet
chickenpoxpati
cours
viremia
estim
analyz
vzv
dna
level
relat
number
day
sinc
onset
rash
use
linear
regress
result
vzv
dna
detect
plasma
serum
specimen
whole
blood
sampl
level
rang
copiesml
neg
sampl
obtain
beyond
day
rash
onset
highest
vzv
dna
level
observ
around
onset
rash
linear
regress
show
signific
invers
relat
vzv
dna
level
plasma
serum
number
day
rash
onset
slope
r
p
highli
similar
find
observ
whole
blood
conclus
despit
assum
cellassoci
natur
vzv
viremia
high
level
vzv
dna
detect
plasma
serum
chickenpox
origin
vzv
dna
compart
requir
studi
provid
conveni
matric
pcr
diagnosi
result
lend
support
assum
cours
viremia
chickenpox
quantit
analys
treatment
vzv
infect
ongo
broadspectrum
pcr
primer
use
analyz
hpvstatu
women
histori
either
two
consecut
cervic
smear
classifi
ascu
mild
dysplasia
one
cervic
smear
show
moder
dysplasia
cervic
scrape
biopsi
obtain
day
group
interv
year
group
mean
day
hpvposit
case
genotyp
revers
hybrid
amplim
innolipa
hpv
prototyp
research
assay
detect
differ
genotyp
group
hpvdna
detect
cervic
smear
biopsi
specimen
n
yield
concord
genotyp
result
wherea
genotyp
discord
among
case
nonident
compat
genotyp
least
one
common
genotyp
contain
addit
genotyp
cervic
scrape
compar
correspond
biopsi
specimen
convers
case
addit
genotyp
found
biopsi
specimen
patient
scrape
biopsi
specimen
contain
addit
genotyp
result
group
ii
highli
similar
group
multipl
hpv
genotyp
frequent
detect
cervic
scrape
compar
correspond
biopsi
specimen
conclus
analysi
cervic
scrape
accur
reflect
spectrum
hpv
genotyp
patient
cervic
region
pcrlipa
offer
valuabl
tool
clinic
epidemiolog
studi
develop
typespecif
vaccin
epsteinbarr
viru
lymphoprolif
diseas
ebvlpd
seriou
complic
allosct
extrem
poor
prognosi
recent
develop
sensit
realtim
taqman
assay
quantit
detect
ebvdna
plasma
use
assay
set
assess
valu
close
follow
ebvdna
plasma
level
monitor
predict
respons
treatment
subsequ
surviv
fourteen
patient
two
center
receiv
sibl
n
match
unrel
donor
mud
n
graft
monitor
frequent
time
ebvlpd
diagnosi
therapi
assess
clinic
respons
therapi
modal
includ
therapi
n
l
interrupt
immunosuppress
si
acyclovir
acv
n
chemotherapi
ctx
n
anticd
monoclon
antibodi
n
donor
lymphocyt
infus
dli
n
seven
patient
complet
respons
therapi
surviv
six
month
ebvlpd
diagnosi
caus
death
includ
progress
ebvlpd
n
graft
versu
host
diseas
gvhd
n
relaps
aml
n
l
absolut
level
ebvdna
time
ebvlpd
diagnosi
predict
respons
surviv
contrast
pattern
ebvdna
level
decreas
versu
increas
within
hour
start
therapi
significantli
predict
clinic
respons
therapi
associ
observ
pattern
ldhlevel
clinic
respons
lymphopenia
associ
poor
outcom
conclud
quantit
monitor
ebvdna
level
start
therapi
ebvlpd
predict
respons
therapi
allow
individu
tailor
differ
treatment
modal
worldwid
evalu
drug
resist
genotyp
qualiti
use
panel
rob
schuurman
brambilla
tom
de
groot
ireen
bender
charl
boucher
dept
virolog
univers
medic
center
heidelberglaan
utrecht
cx
netherland
enva
univers
medic
center
utrecht
netherland
neri
boston
usa
genotyp
drug
resist
determin
current
appli
absenc
interlaboratori
standard
studi
perform
evalu
accuraci
sequenc
protocol
detect
mutat
sequenc
heterogen
rt
proteas
gene
code
panel
five
plasma
sampl
panel
infect
differ
proport
two
strain
sent
experienc
genotyp
laboratori
worldwid
analys
nucleotid
sequenc
total
dataset
receiv
laboratori
sampl
wild
type
five
resistanceassoci
site
gene
correctli
identifi
laboratori
rt
proteas
fewer
complet
correct
sequenc
obtain
sampl
mutant
site
rt
proteas
five
mutat
detect
mixtur
wild
type
mutant
less
half
laboratori
gene
independ
sequenc
technolog
use
sampl
harbor
equal
mixtur
wildtyp
mutant
well
complet
mutant
sampl
presenc
mutant
genotyp
underestim
may
implic
clinic
applic
genotyp
result
ongo
qualiti
assur
monitor
warrant
kaposi
sarcoma
associ
herpesviru
gene
express
latneci
lytic
replic
reveal
dna
array
paul
kellam
chri
boshoff
richard
jenner
cancer
research
campaign
viral
oncolog
depart
oncolog
univers
colleg
london
london
uk
wohl
virion
centr
dept
molecular
patholgi
windey
inst
univers
colleg
london
cleveland
street
london
uk
kaposi
sarcomaassoci
herpesviru
kshv
associ
three
human
tumor
kaposi
sarcoma
ks
primari
effus
lymphoma
pel
multicentr
castleman
diseas
mcd
kshv
encod
number
homolog
cellular
protein
involv
cell
cycl
signal
transduct
modul
host
immun
respons
viru
complement
open
read
frame
orf
express
minor
characteris
individu
construct
nylon
membran
base
dna
array
allow
express
everi
known
orif
kshv
measur
simultan
pelderiv
cell
line
use
studi
express
kshv
latenc
induct
lytic
replic
tetradecanoylphorbol
acet
tpa
multipl
sampl
taken
hour
lytic
replic
express
gene
determin
cluster
analysi
bioinformat
tool
arrang
gene
accord
express
profil
reveal
correl
express
assign
gene
function
consist
known
stage
viru
life
cycl
addit
global
natur
analysi
much
inform
gain
function
viral
gene
previous
examin
transcript
splice
open
read
frame
orf
kaposi
sarcoma
associ
herpesviru
kshv
primari
effus
lymphoma
cell
line
latent
infect
kshv
virolog
three
gene
encod
orf
vflip
vcyclin
lna
transcrib
common
transcript
start
site
cell
latenc
lytic
cycl
result
transcript
splice
yield
kb
messag
encod
lna
vcyclin
vflip
kb
bicistron
messag
encod
vcyclin
vflip
investig
whether
vflip
protein
could
express
vcyclinvflip
messag
utilis
bicistron
luciferas
report
system
gene
renilla
firefli
luciferas
utilis
differ
substrat
clone
tandem
downstream
rna
polymeras
promot
fragment
dna
immedi
upstream
initi
codon
vflip
clone
two
luciferas
gene
rel
express
two
luciferas
one
direct
put
ire
sequenc
capdepend
ribosom
scan
use
compar
activ
differ
dna
fragment
minimum
fragment
immedi
upstream
vflip
start
codon
found
direct
effici
express
downstream
firefli
luciferas
activ
ire
orient
depend
enhanc
method
use
inhibit
capdepend
translat
first
demonstr
ire
element
encod
dna
viru
may
repres
novel
mechan
wherebi
kshv
control
protein
express
aurich
inhibitori
sequenc
late
human
papillomaviru
type
mrna
stefan
scwartz
marcu
sokolowski
margaret
rush
anett
carlsson
depart
medic
biochemistri
microbiolog
bmc
uppsala
univers
husargatan
box
uppsala
sweden
human
papillomaviru
hpv
life
cycl
strictli
link
epitheli
differenti
program
product
viru
particl
depend
termin
cell
differenti
viru
structur
protein
therefor
detect
upper
layer
differenti
cell
infect
epithelium
abund
viru
particl
detect
vivo
may
vari
variou
hpv
type
research
group
interest
regul
express
hpv
structur
protein
found
late
mrna
contain
inhibitori
sequenc
utr
map
nucleotid
aurich
sequenc
two
auuuaand
three
uuuuumotif
function
element
replac
two
us
two
cs
five
element
inactiv
inhibitori
sequenc
element
act
via
bimod
mechan
presenc
inhibitori
sequenc
mrna
result
rapid
degrad
inhibit
translat
two
effect
studi
separ
result
demonstr
aurich
element
inhibit
translat
cap
polyadenyl
mrna
suggest
factor
interact
inhibitori
sequenc
disturb
interact
polya
tail
cap
structur
cytoplasm
kda
protein
bind
specif
auuua
element
identifi
addit
nuclear
hur
hnrnp
c
protein
interplay
cellular
factor
aurich
inhibitori
rna
element
may
regul
express
level
cell
differenti
depend
manner
express
transcript
unit
engin
coronaviru
deriv
minigenom
fulllength
genom
alonso
sola
cm
izeta
lui
enjuan
centro
nacion
de
csic
depart
molecular
cell
biolog
campu
universidad
autonoma
madrid
spain
express
engin
transcript
unit
studi
use
helper
depend
express
system
base
transmiss
gastroenter
viru
tgev
deriv
minigenom
rna
express
level
increas
use
twostep
amplif
system
base
cmv
promot
coupl
polll
driven
transcript
nucleu
replic
support
helper
viru
polymeras
cytoplasm
collect
tgev
transcript
regulatori
sequenc
trss
includ
variabl
number
nucleotid
flank
core
sequenc
cuaaac
end
introduc
minigenom
express
engin
mrna
encod
bglucuronidas
gu
evalu
vitro
vivo
express
gu
gene
stabl
passag
tissu
cultur
express
level
around
mg
per
cell
gu
protein
obtain
optim
transcript
regulatori
sequenc
overcom
limit
helperdepend
system
singlegenom
express
vector
develop
promot
target
rna
recombin
helper
viru
minigenom
carri
foreign
transcript
unit
also
infecti
cdna
clone
deriv
tgev
engin
express
high
level
cell
green
fluoresc
protein
gpt
achiev
cdna
infecti
cdna
promis
vaccini
vector
induc
secretori
immun
gene
therapi
regul
viral
genom
express
result
complex
cooper
viral
protein
host
cell
factor
report
character
novel
cellular
factor
share
homolog
specif
cysteinerich
ctermin
domain
bhlhrepressor
protein
imfa
synthesi
new
factor
call
hic
human
imfa
domaincontain
protein
control
translat
level
two
differ
codon
atg
upstream
nonatg
translat
initi
allow
product
two
protein
isoform
respect
show
hic
protein
isoform
present
differ
subcellular
local
mainli
distribut
throughout
cytoplaxm
wherea
target
nucleolu
moreov
tri
understand
function
hic
found
isoform
stimul
cell
express
luciferas
report
gene
driven
htlvi
long
termin
repeat
ltr
presenc
viral
transactiv
tax
demonstr
mutagenesi
imfalik
domain
hic
involv
regul
lastli
also
show
hic
abl
downregul
luciferas
express
ltr
induc
viral
transactiv
tat
result
propos
hic
imfa
repres
two
member
new
famili
protein
regul
gene
express
character
particular
cysteinerich
ctermin
domain
unit
kingdom
nation
extern
qualiti
assess
scheme
microbiolog
rna
quantif
profici
scheme
vla
jame
k
gerrard
j
hawkin
k
ohara
jv
parri
central
public
health
laboratori
colindal
avenu
london
uk
unit
kingdom
nation
extern
qualiti
assess
scheme
microbiolog
pilot
four
profici
test
distribut
rna
quantif
distribut
consist
pair
specimen
deriv
singl
rna
posit
plasma
dilut
normal
human
plasma
specimen
freezedri
test
six
refer
laboratori
distribut
clinic
interpret
rna
quantif
assay
result
differ
log
copiesml
sequenti
specimen
consid
signific
scheme
therefor
design
focu
differ
log
hiv
rna
copiesml
pair
sampl
rather
absolut
valu
would
also
avoid
bia
due
observ
differ
absolut
valu
obtain
differ
manufactur
kit
dilut
employ
prepar
specimen
result
differ
two
specimen
approxim
one
log
copyml
first
distribut
specimen
design
order
log
copiesml
log
copiesml
three
distribut
specimen
design
order
log
copiesml
log
copiesml
percentag
laboratori
report
differ
log
concentr
respect
laboratori
variat
hiv
viral
load
test
independ
run
control
program
rob
schuurman
jolanda
tijnagel
dept
virolog
univers
medic
center
utrecht
heidelberglaan
cx
utrecht
netherland
intern
molecular
servic
utrecht
netherland
hiv
quantif
assay
wide
appli
determin
monitor
viral
load
patient
antivir
therapi
independ
monitor
interlaboratori
interkit
lot
perform
characterist
may
import
tool
perform
multicent
research
clinic
trial
attempt
set
monitor
system
independ
run
control
irc
contain
rna
copiesml
develop
use
em
quantifi
viral
stock
irc
aliquot
singl
use
ml
volum
distribut
among
particip
laboratori
use
amplicor
monitor
assay
irc
run
parallel
regular
kit
control
everi
viral
load
run
result
irc
kit
control
addit
inform
kit
lot
number
kit
version
assay
type
normal
ultrasensit
technician
name
report
real
time
central
databas
analys
report
month
followup
viral
load
run
analys
interlaboratori
differ
observ
irc
result
indic
differ
mean
valu
well
sd
interkitlot
comparison
demonstr
statist
signific
differ
lot
number
control
could
also
use
evalu
perform
ultrasensit
version
monitor
assay
ultrasensit
assay
result
highli
correl
irc
result
obtain
regular
version
similar
high
level
correl
observ
result
obtain
manual
microwel
plate
assay
result
obtain
coba
amplicor
irc
demonstr
import
tool
independ
long
term
monitor
viral
load
assay
perform
larg
scale
aim
euqcca
establish
extern
qualiti
control
programm
assess
evalu
exist
evolv
nucleic
acid
amplif
procedur
diagnost
virolog
purpos
profici
panel
prepar
molecular
detect
quantit
variou
virus
includ
bloodborn
virus
bbv
may
profici
panel
hivrna
hcvrna
hbvdna
distribut
laboratori
countri
februari
second
distribut
took
place
panel
consist
neg
sampl
posit
sampl
variou
concentr
genotyp
viru
major
lab
use
commerci
assay
qualit
quantit
examin
sampl
roch
assay
use
frequent
falseposit
rate
well
panel
exclud
first
hbvdna
panel
falseneg
rate
difficult
determin
larg
variat
detect
limit
variou
assay
howev
limit
clearli
posit
sampl
falseneg
rate
low
analysi
quantit
result
show
consider
variat
viral
load
due
variabl
within
assay
variou
manufactur
gener
standard
deviat
mean
viral
load
valu
obtain
bdna
assay
significantli
lower
obtain
type
assay
agreement
result
assay
differ
manufactur
gener
good
accept
frequent
circul
genotyp
industri
countri
less
good
less
common
genotyp
result
indic
consider
improv
molecular
detect
quantit
bbv
achiev
recent
year
particularli
use
commerci
assay
standard
includ
less
common
genotyp
howev
still
need
panel
qualiti
control
nucleic
acid
amplif
herp
simplex
viru
hsv
l
schloss
lind
f
lundqvist
ki
falk
p
cinqu
p
aim
extern
qualiti
control
eqc
nucleic
acid
amplif
naa
materi
method
auspic
european
union
concert
action
qualiti
control
nucleic
acid
amplif
diagnost
virolog
two
extern
qualiti
control
profici
panel
produc
hsv
type
strain
macintyr
hsv
type
strain
ms
obtain
atcc
cultiv
african
green
monkey
kidney
cell
heat
inactiv
freezedri
endpoint
pcr
posit
result
determin
test
refer
laboratori
amount
hsv
dna
dilut
determin
quantit
pcr
refer
laboratori
panel
contain
sampl
hsv
posit
varicellazost
viru
posit
neg
sampl
distribut
european
laboratori
result
laboratori
submit
data
set
data
set
record
satisfactori
better
result
laboratori
use
qualit
inhous
pcr
method
singl
pcr
geldetect
lower
sensit
singl
pcr
probedetect
nest
pcr
small
number
dataset
report
fals
posit
result
result
second
panel
present
result
indic
laboratori
satisfactori
hsv
pcr
perform
improv
requir
eqc
profici
test
import
tool
monitor
diagnost
test
qualiti
parvoviru
replic
erythroid
progenitor
cell
bone
marrow
foetal
liver
small
number
human
cell
line
order
better
understand
analys
replic
cycl
perform
compar
infect
bone
marrow
cell
differ
erythroblastoid
mega
karyobl
astoid
cell
line
follow
vitro
infect
nucleic
acid
characteris
respect
genom
replic
intermedi
transcript
pattern
product
capsid
protein
cell
line
test
prove
suscept
viru
infect
two
differ
pattern
restrict
replic
observ
first
pattern
observ
cell
viral
singlestrand
ss
dna
convert
doublestrand
ds
replic
intermedi
ident
found
bone
marrow
cell
full
pattern
viral
transcript
observ
howev
replic
transcript
restrict
small
subset
cell
product
capsid
protein
detect
second
pattern
observ
cell
viral
ssdna
convert
dsdna
replic
intermedi
consequ
transcript
viral
genom
occur
conclus
studi
provid
evid
presenc
two
differ
level
restrict
viru
replic
first
level
restrict
occur
relat
uncoat
viral
genom
andor
convers
viral
ssdna
replic
dsdna
second
level
restrict
occur
relat
product
viral
capsid
protein
propag
hepat
b
viru
cell
edward
dornan
lackenbi
jazayeri
e
depla
ottavaer
k
devrees
wf
carman
divis
virolog
institut
biolog
life
scienc
univers
glasgow
church
street
glascow
uk
innogenet
nv
ghent
belgium
avail
continu
cell
line
suscept
infect
hbv
would
signific
advanc
studi
viru
allow
studi
earli
event
viral
replic
analys
function
characterist
hbv
variant
recent
evid
phospholipid
bind
protein
annexin
v
receptor
hbv
accumul
addit
infect
rat
cell
line
stabli
transfect
human
av
gene
term
cell
line
infect
hbv
present
evid
role
annexinv
hbv
infect
demonstr
hbv
propag
cell
line
hbv
human
sera
cultur
supernat
sn
cell
use
infect
cell
cell
plate
coverslip
well
plate
infect
carri
hbeag
serum
contain
genom
equivalentsml
five
day
cultur
supernat
cell
geneqml
overnight
incub
cell
either
wash
thoroughli
least
five
time
pb
subject
mild
trypsinis
presenc
chicken
serum
remov
residu
innoculum
cultur
sn
stage
becam
pcr
neg
cell
sn
assay
variou
time
post
infect
microscopi
hbcag
stain
nucleu
pcr
cultur
sn
cccdna
gener
upon
viral
entri
cell
specif
pcr
harvest
cell
sn
cell
prove
posit
hbv
assay
time
cell
infect
assess
presenc
dmso
interestingli
recombin
av
augment
infect
cell
later
observ
may
explain
bind
av
phophatidyl
serin
hbv
envelop
concomit
bind
hbsag
subsequ
fusion
hepatocyt
membran
sn
initi
infect
cell
use
infect
fresh
fto
cell
similar
outcom
primari
infect
viru
propag
manner
least
two
passag
reliabl
reproduc
thu
indic
valu
cell
line
vitro
studi
hbv
exampl
posit
assess
replic
compet
variant
natur
drug
eg
lamivudin
select
induct
papilloma
mous
model
use
recombin
bovin
papillomaviru
type
dna
andrea
pawellek
g
hewlett
j
kreuter
h
robsamenwaigmann
bayer
ag
busi
group
pharma
antiinfect
research
virolog
aprath
weg
wuppert
germani
virologi
bayer
ag
wuppert
germani
institut
pharmazeutisch
technologi
universitat
frankfurt
main
germani
due
fact
papillomavirus
replic
monolay
cell
cultur
classic
anim
model
exampl
use
bovin
papillomaviru
well
transplant
model
use
studi
featur
papillomaviru
replic
cycl
model
reli
infect
viru
particl
allow
genet
studi
carri
eas
gene
function
analys
manipul
clone
dna
decid
investig
whether
recombin
also
induc
wart
recent
establish
mous
xenograft
model
papillomaviru
infect
viral
dna
isol
bovin
wart
phenolchloroform
extract
identifi
extract
cut
uniqu
hind
iii
restrict
site
clone
pbluescript
ii
sk
vector
amplif
e
coli
viral
dna
recov
vector
relig
calf
scrotal
skin
inject
relig
viral
dna
graft
dorsum
sever
combin
immunodefici
scid
mice
five
month
transfect
tumour
develop
show
histolog
featur
papillomaviru
infect
southern
blot
hybridis
use
probe
demonstr
presenc
dna
transfect
transplant
rtpcr
reveal
express
gene
typic
fibropapilloma
model
recombin
dna
shown
infecti
induc
wart
model
use
mutat
analysi
therefor
better
understand
regul
papillomaviru
infect
five
natur
occur
variant
clone
pcdna
express
vector
driven
cmv
promot
equival
variant
stop
codon
insert
includ
intern
control
construct
transfect
cell
stabl
celllin
establish
select
cell
prolifer
assay
fociform
assay
cellcycl
analysi
facscan
perform
cell
line
cellcycl
profil
construct
analys
presenc
epiderm
growth
factor
indic
control
similar
percentag
cell
phase
contrast
caus
statist
signific
decreas
increas
phase
variant
differ
markedli
refer
isol
alter
cell
cycl
profil
accompani
mark
increas
cellgrowth
overal
appear
due
variant
substitut
amino
acid
stabilis
first
l
third
ahelic
v
protein
timecours
experi
current
analys
determin
whether
variant
differenti
effect
cyclin
depend
kinas
inhibitor
level
cyclin
b
data
indic
variant
differ
biolog
activ
may
contribut
enhanc
pathogen
particular
variant
adenoviru
dna
polymeras
domain
residu
contribut
activ
viral
replic
huant
liu
jame
h
naismith
ronald
hay
centr
biomolecular
scienc
bm
build
univers
st
andrew
north
haugh
st
andrew
uk
adenoviru
dna
polymeras
member
dna
polymeras
famili
use
protein
primer
initi
dna
synthesi
contain
motif
characterist
proofread
exonucleas
domain
locat
ntermin
region
sever
dna
polymeras
motif
locat
ctermin
region
determin
mechan
role
conserv
residu
adenoviru
dna
polymeras
dna
replic
twentytwo
sitedirect
mutat
introduc
conserv
dna
polymeras
motif
ctermin
region
mutant
express
insect
cell
use
baculoviru
express
system
mutant
test
dna
bind
activ
abil
interact
ptp
dna
polymeras
catalyt
activ
abil
particip
initi
adenoviru
dna
replic
mutant
phenotyp
identifi
function
domain
within
adenoviru
dna
polymeras
allow
discrimin
role
conserv
residu
variou
activ
carri
protein
use
function
data
studi
previous
publish
structur
bacteriophag
dna
polymeras
wang
et
al
cell
domain
organis
adenoviru
dna
polymeras
envisag
similar
dna
polymeras
catalyt
site
compos
conserv
motif
ygdtd
pol
dcgmya
pol
kllsnalyg
pol
addit
residu
lie
outsid
conserv
region
also
requir
dna
polymeras
activ
herp
simplex
viru
type
null
mutant
packag
replic
amplicon
dna
rel
effici
viral
dna
iain
porter
nigel
stow
mrc
virolog
unit
church
street
glasgow
uk
herp
simplex
viru
type
gene
encod
alkalin
nucleas
although
absolut
essenti
replic
null
mutant
produc
fold
less
viabl
viru
wt
suggest
alkalin
exonucleas
function
remov
branch
structur
high
molecular
weight
concatemer
dna
prior
cleavag
packag
monomer
genom
viral
capsid
failur
process
dna
result
unstabl
packag
dna
capsid
fail
egress
nucleu
investig
role
replic
packag
plasmid
amplicon
contain
replic
origin
dna
encapsid
signal
cell
transfect
amplicon
superinfect
either
wt
null
mutant
ah
patel
et
al
j
gen
virol
replic
amplicon
viral
genom
dna
infect
cell
similarli
reduc
approxim
compar
wt
contrast
cell
infect
exhibit
reduct
packag
genom
dna
compar
reduct
amplicon
dna
packag
effect
amplicon
replic
packag
could
complement
cotransfect
plasmid
express
overlap
gene
also
demonstr
amplicon
gener
high
molecular
weight
concatem
recombin
high
frequenc
analog
replic
viral
dna
preliminari
data
addit
indic
absenc
increas
proport
dna
lack
packag
signal
may
encapsid
nest
multiplex
polymeras
chain
reaction
diagnosi
cutan
herp
simplex
herp
zoster
infect
comparison
electron
microscopi
peter
coyl
jain
wyatt
hj
oneil
c
mccaughey
region
viru
laboratori
royal
victoria
hospit
grosvenor
road
belfast
northern
ireland
uk
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
common
caus
cutan
mucocutan
vesicular
erupt
laboratori
diagnost
techniqu
includ
tzanck
smear
electron
microscopi
em
antigen
detect
viral
cultur
paper
describ
nest
multiplex
polymeras
chain
reaction
nmpcr
respect
sensit
vzv
assay
use
salvag
capac
slide
alreadi
process
em
b
frontlin
assay
prospect
process
specimen
sixtytwo
glass
slide
vesicl
lymphscrap
patient
suspect
cutan
herpet
lesion
examin
clinic
present
describ
atypicalnot
specifi
vzv
hsv
involv
erupt
divers
anatom
site
includ
genitalia
specimen
posit
em
nmpcr
respect
give
compar
sensit
em
nmpcr
identifi
vzv
infect
clinic
detail
indic
either
hsv
vzv
nmpcr
statist
like
reactiv
versu
x
p
wherea
em
versu
x
p
clinic
detail
indic
vzv
hsv
nmpcr
statist
like
confirm
vzv
versu
x
p
hsv
versu
x
p
respect
two
suspect
hsv
suspect
vzv
infect
shown
vzv
hsv
respect
nmpcr
simultan
detect
identif
rubella
measl
parvoviru
virus
multiplex
pcr
juan
e
fernando
de
ori
mar
mosquera
centro
nacion
de
microbiologfa
instituto
de
salud
carlo
ctra
majadahondapozuelo
sn
majadahonda
madrid
spain
parvoviru
measl
viru
mv
rubella
viru
rv
import
caus
exanthemat
diseas
moreov
caus
sever
import
complic
congenit
rubella
syndrom
postinfecti
encephalopathi
subacut
scleros
panenceph
produc
mv
transient
aplast
crisi
chronic
anemia
hidrop
fetali
clinic
featur
exanthema
caus
virus
similar
differenti
diagnosi
often
requir
report
describ
diagnost
method
abl
detect
simultan
viral
genom
three
virus
multiplex
rtpcr
two
pair
primer
first
nest
reaction
design
viru
target
gene
el
glycoprotein
case
rv
nucleoprotein
mv
nucleogapsid
protein
size
amplif
fragment
obtain
nest
amplif
differ
viru
easili
differenti
agaros
gel
electrophoresi
sensit
estim
dna
copytub
genom
cdna
copi
mv
rv
genom
techniqu
allow
us
detect
mv
pharyng
exud
measl
outbreak
two
cerebrospin
fluid
patient
postmeasl
enceph
rv
two
pharyng
exud
one
urin
newborn
congenit
rubella
syndrom
three
pharyng
exud
postvaccin
children
also
detect
serum
specimen
erythema
infectiosum
outbreak
conclud
techniqu
seem
use
complement
serolog
diagnosi
diseas
allow
recoveri
genom
materi
use
subsequ
studi
special
conveni
surveil
activ
measl
erad
program
introduct
aim
hous
rtpcr
procedur
describ
investig
enteroviru
mening
tend
labori
difficult
control
project
aim
evalu
recentlydevelop
panenteroviru
nasba
diagnost
investig
possibl
enteroviru
infect
method
assay
utilis
kitbas
reagent
extract
amplif
detect
amplifi
product
nuclisen
basic
kit
organon
teknika
ltd
togeth
hous
design
primer
probe
base
noncod
region
result
conclus
specif
nasba
assay
good
sensit
assay
detect
wide
rang
enterovirus
approxim
input
assay
also
pick
addit
viru
type
readili
propag
vitro
basic
kit
nasba
gave
equival
sensit
labori
hous
rtpcr
nasba
assay
control
profici
panel
materi
date
result
prospectivelyanalys
clinic
sampl
n
concord
hous
rtpcr
basic
kit
result
avail
within
work
day
compar
day
rtpcr
cultur
respect
basic
kit
nasba
suitabl
diagnost
molecular
amplif
method
analysi
enteroviru
sequenc
csf
stool
respiratori
specimen
use
kitbas
reagent
fast
turnaround
result
compar
hous
rtpcr
enhanc
costeffect
qualiti
control
molecularbas
diagnost
procedur
investig
possibl
enteroviru
mening
nowaday
artifici
insemin
main
rout
insemin
sow
make
ai
station
play
pivot
role
transmiss
viral
infect
last
outbreak
classic
swine
fever
csf
netherland
proven
viru
could
also
transmit
semen
porcin
reproduct
respiratori
syndrom
viru
pprsv
caus
reproduct
failur
sow
respiratori
distress
piglet
rel
new
diseas
firstli
describ
us
emerg
pig
europ
sinc
spread
rapidli
contribut
significantli
econom
loss
pig
industri
know
transmiss
prrsv
occur
boar
semen
typic
boar
demonstr
signific
clinic
sign
infect
seroconvers
viremia
may
correl
shed
viru
semen
report
describ
develop
realtim
pcr
use
light
cycler
roch
technolog
detect
prrsv
csfv
semen
main
advantag
system
speed
pcr
make
high
throughput
possibl
ii
use
specif
hybrid
probe
iii
pcr
analysi
done
close
system
decreas
risk
fals
posit
amplic
contamin
pcr
valid
use
semen
sampl
boar
experiment
infect
pprsv
csfv
semen
sampl
test
viru
isol
bioassay
pcr
conclud
pcr
describ
easi
perform
fast
reproduc
sensit
viru
isol
bioassay
mechan
coxsackieviru
induc
damag
human
pancreat
beta
cell
roivainen
rasilainen
p
ylipaasto
r
nissinen
j
ustinov
l
bouwensu
dl
eizirika
tapan
hovi
otonkoski
enteroviru
laboratori
depart
virolog
nation
public
health
institut
ktl
mannerheiminti
helsinki
finland
univers
helsinki
helsinki
finland
vrije
universiteit
brussel
brussel
belgium
insulin
depend
diabet
mellitu
iddm
sever
chronic
diseas
insulin
produc
betacel
langerhan
islet
pancrea
gradual
destroy
use
primari
human
adult
beta
cell
tri
find
mechan
differ
enterovirus
may
induc
acceler
process
eventu
lead
iddm
accord
result
signific
function
impair
seen
coxsacki
b
viru
infect
minor
infect
cell
becam
apoptot
shown
nuclear
morpholog
increas
situ
dna
end
label
infect
cell
die
pyknosi
character
highli
distort
nuclei
condens
intact
chromatin
contrast
cbv
genet
close
relat
cbv
caus
immedi
advers
effect
human
beta
cell
despit
replic
well
diabetogen
properti
enterovirus
studi
found
divid
two
major
group
exampl
sever
serotyp
echoviru
cytolyt
like
cbv
lesscytolyt
serotyp
well
differenti
epitheli
cell
bronchiolar
epithelium
elimin
viral
infect
cell
mous
lung
hyperplasia
slough
keith
gottleib
lui
p
villarr
depart
molecular
biolog
biochemistri
univers
california
irvin
biolog
scienc
ii
box
irvin
ca
usa
lung
resili
organ
must
avoid
overt
tissu
damag
viru
infect
induc
immun
respons
prevent
loss
function
vital
compon
respiratori
system
lab
investig
acut
stage
infect
mous
lung
virus
indigen
wild
mous
popul
follow
natur
rout
infect
use
polyomaviru
py
model
demonstr
innat
nonimmun
respons
differenti
epitheli
cell
clara
bronchi
bronchiol
expel
viru
newborn
adult
mice
intranas
inocul
py
lung
obtain
start
two
day
post
infect
formalin
fix
paraffin
embed
section
made
evalu
situ
hybrid
immunohistochemistri
hematoxylin
eosin
stain
perform
analyz
viral
replic
gene
express
viral
host
protein
histopatholog
observ
respect
clear
hyperplasia
clara
cell
evidenc
presenc
clara
cell
secretori
protein
began
day
infect
continu
hour
result
eventu
slough
multipl
layer
cell
prior
lymphocyt
infiltr
slough
elimin
apic
cell
posit
py
dna
underli
cell
express
py
earli
protein
leav
normal
bronchiolar
epithelium
virtual
free
detect
viru
similar
phenomenon
report
sendai
viru
distinctli
differ
viru
py
appear
ubiquit
though
rare
analyz
lung
infect
virus
tropic
bronchiolar
epithelium
hepat
c
viru
core
protein
uniqu
region
direct
matur
intracellular
target
protein
john
mclauchlan
r
graham
hope
mrc
virolog
unit
institut
virolog
church
street
glasgow
uk
hcv
core
protein
form
capsid
shell
virion
implic
modul
number
key
cellular
process
aim
characteris
fundament
properti
protein
identifi
sequenc
influenc
behaviour
sequenc
comparison
postul
core
consist
three
distinct
domain
ntermin
domain
high
content
basic
amino
acid
region
amino
acid
absent
sequenc
relat
flaviand
pestivirus
therefor
uniqu
final
transmembran
segment
contain
signal
peptid
glycoprotein
el
transmembran
segment
remov
capsid
protein
flavivirus
viral
proteas
hcv
process
matur
form
core
perform
cellular
proteas
data
indic
hydrophob
domain
resid
within
uniqu
domain
hcv
core
necessari
effici
product
matur
protein
also
critic
protein
stabil
henc
need
viral
proteas
matur
flaviviru
capsid
protein
substitut
hcv
core
protein
sequenc
direct
process
sole
cellular
machineri
uniqu
domain
also
function
target
core
intracellular
lipid
droplet
sequenc
similar
oleosin
protein
locat
equival
structur
plant
cell
role
uniqu
sequenc
hcv
discuss
light
recent
data
relationship
effici
viru
product
coordin
process
matur
flaviviru
capsid
protein
non
structur
nss
protein
rift
valley
fever
phleboviru
util
microtubul
network
transport
nucleu
le
bouloy
fz
yadani
kohl
p
gounon
p
denoulet
institut
pasteur
rue
du
dr
roux
pari
cedex
franc
colleg
de
franc
pari
franc
rift
valley
fever
viru
rvfv
arthropodborn
viru
bunyavirida
famili
genu
phleboviru
sporad
caus
widespread
epizooticsepidem
throughout
africa
respons
hemorrhag
fever
among
member
famili
phleboviru
genu
rvfv
uniqu
nonstructur
protein
nss
form
filament
structur
nuclei
infect
cell
presenc
viral
compon
nucleu
unexpect
sinc
replic
rvfv
well
member
famili
occur
cytoplasm
investig
mechan
filament
format
express
nss
protein
via
recombin
semliki
forest
replicon
demonstr
protein
alon
abl
form
nuclear
filament
carboxytermin
amino
acid
play
essenti
role
format
filament
nuclear
local
domain
contain
two
serin
residu
phosphoryl
howev
phosphoryl
seem
play
import
role
properti
protein
use
yeast
twohybrid
system
found
nss
interact
specif
betatubulin
exist
interact
infect
cell
confirm
biochem
analys
immunofluoresc
assay
nss
copurifi
coloc
microtubul
appear
function
microtubuleassoci
protein
domain
nss
interact
betatubulin
map
within
ntermin
amino
acid
express
nss
mutant
domain
delet
found
mutat
protein
remain
cytoplasm
demonstr
interact
nss
microtubul
essenti
transport
protein
nucleu
characteris
immunnmodul
influenc
respiratori
syncyti
viru
matrixprotein
interaxt
nfkappab
complex
kerstin
reimer
chrisitan
roder
hermann
werchau
medic
microbiolog
virolog
ruhrunivers
bochum
univers
street
bochum
germani
respiratori
syncyti
viru
rsv
infect
result
persist
activ
nuclear
factor
kappa
b
lung
epitheli
cell
express
rsv
protein
cell
follow
detect
activ
f
b
electrophoret
mobil
shift
assay
emsa
show
matrixprotein
abl
activ
nf
kappa
b
contrast
rsv
core
protein
result
confirm
report
gene
construct
consist
luciferas
gene
regul
nf
kappa
b
enhanc
element
interestingli
ntermin
delet
mutant
abl
induc
nf
kappa
b
respons
immunoprecipit
follow
western
blot
reveal
interact
directli
nf
kappa
b
complex
confoc
laser
microscopi
well
cellular
subfraction
show
part
transloc
nucleu
timeconsist
activ
nf
kappa
b
find
suggest
besid
function
antitermin
factor
viral
transcript
particip
modul
immun
system
caus
rsv
interact
nf
kappa
b
complex
background
clinic
featur
associ
mani
viral
infect
cn
non
specif
remain
often
undiagnos
patient
admit
hospit
clinic
manifest
enceph
follow
neurolog
deterior
unknown
origin
includ
studi
combin
evalu
clinic
data
result
diagnost
serolog
test
polymeras
chain
reaction
pcr
carri
cerebrospin
fluid
csf
broncho
alveolar
lavag
bal
may
shed
light
aetiolog
case
enceph
aim
identifi
undiagnos
case
measl
cn
involv
method
retrospect
analysi
perform
adult
patient
admit
hospit
enceph
follow
neurolog
deterior
unknown
origin
mean
age
sampl
date
serum
csf
sampl
test
presenc
igm
antibodi
tickborn
enceph
viru
tbev
dengu
viru
dv
measl
viru
mv
result
clinic
featur
report
fever
headach
facial
weak
alter
mental
statu
seizur
impair
hear
motor
disturb
limb
paralysi
respiratori
distress
igm
serum
csf
antibodi
mv
found
patient
one
patient
borderlin
posit
result
found
mv
infect
confirm
borderlin
igm
posit
patient
show
mvrna
rt
pcr
broncho
alveolar
lavag
evid
tbev
dengu
viru
infect
found
conclus
identif
three
case
measl
enceph
among
adult
patient
enceph
unknown
origin
indic
condit
tend
overlook
continu
elimin
mv
develop
countri
human
infect
children
acut
febril
ill
seizur
georg
kamkamidz
maia
butsashvili
nino
gochitashvili
lela
abashidz
tengiz
tsertsvadz
georgian
aid
clinic
immunolog
research
center
al
kazbegi
avenu
tblisi
georgia
fogarti
intern
center
human
one
recent
discov
herpesvirus
primari
infect
caus
agent
roseola
infantum
exanthem
subitum
frequent
associ
nonspecif
febril
ill
children
age
year
goal
studi
investig
infect
children
acut
febril
ill
complic
seizur
twentytwo
children
month
age
acut
febril
ill
seizur
enrol
studi
blood
sampl
obtain
moment
first
examin
emerg
depart
day
thereaft
igg
igm
antibodi
evalu
indirect
immunofluoresc
assay
dna
detect
nest
pcr
assay
peripher
blood
mononuclear
cell
children
age
without
acut
ill
studi
control
primari
infect
found
patient
studi
group
case
igm
pcr
sampl
patient
pcr
igg
second
sampl
case
pcr
sampl
group
past
infect
found
patient
case
igg
pcr
sampl
child
igg
pcr
sampl
nine
children
show
infect
igg
igm
pcr
primari
infect
found
control
group
past
infect
document
children
primari
infect
associ
acut
febril
ill
seizur
earli
childhood
hospitalrel
hepat
c
viru
hcv
infect
continu
occur
despit
introduct
blood
donor
screen
evalu
problem
difficult
due
frequent
silent
cours
infect
lack
prospect
studi
scarc
data
patient
patient
transmiss
set
hemodialysi
unit
report
transmiss
hcv
nine
pediatr
patient
oncolog
ward
index
case
twoyearold
child
hospit
intraven
feed
sinc
birth
octob
develop
clinic
hepat
hcv
infect
confirm
posit
hgvpcr
seroconvers
antihcv
sourc
infect
could
trace
precautionari
hygien
measur
prevent
hcv
transmiss
taken
patient
remain
hospit
follow
month
eight
addit
children
treat
overlap
period
becam
infect
hcv
sequenc
three
hcv
genom
region
ntr
hypervari
region
show
high
homolog
genotyp
mode
viru
transmiss
could
establish
screen
famili
member
medic
staff
blood
product
assum
involuntari
nonobserv
precautionari
measur
respons
outbreak
meanwhil
index
patient
receiv
combin
liver
small
bowel
transplant
remain
hcvpcr
neg
serum
live
home
four
patient
hcvrna
posit
two
hcvrna
neg
two
die
oncolog
diseas
detect
enterovir
sequenc
frozen
spinal
cord
sampl
japanes
al
patient
bruno
lina
pierric
giraud
beaulieux
seiitsu
ono
n
shimizu
guy
chazot
servic
de
neurologi
b
pital
neurologiqu
pierr
wertheim
bvd
pinel
lyon
cedex
franc
centr
nation
de
pour
la
gripp
laboratoir
de
virologi
de
virologi
ea
domain
rockefel
lyon
cedex
franc
depart
neurolog
teikyo
uni
school
medicin
ichihara
hospit
anesaki
lchiahra
japan
possibl
associ
persist
enteroviru
infect
develop
amyotroph
later
sclerosi
al
suggest
detect
locat
enterovir
sequenc
spinal
cord
al
case
compar
control
case
use
revers
transcriptas
polymeras
chain
reaction
rt
pcr
direct
rt
situ
pcr
rtispcr
formalinfix
sampl
respect
result
confirm
second
studi
confirm
second
studi
carri
frozen
spinal
cord
sampl
collect
japanes
patient
sampl
blind
japan
subsequ
sent
dri
ice
french
lab
use
adapt
procedur
total
rna
extract
sampl
extract
process
enteroviru
detect
rtpcr
non
code
region
among
sampl
five
al
case
nonal
control
among
five
al
case
three
posit
enteroviru
detect
compar
control
pcr
product
obtain
control
patient
go
sequenc
even
result
second
studi
dramat
previou
studi
nonambigu
confirm
enterovir
sequenc
detect
spinal
cord
sampl
al
patient
link
elucid
presenc
sequenc
develop
al
femal
neonat
deliv
caesarean
section
week
gestat
fetal
distress
apgar
score
minut
respect
mother
prematur
ruptur
membran
sign
infect
fever
leukocytosi
immedi
birth
bacteri
cultur
taken
child
receiv
amoxycillin
cefotaxim
day
transfer
nicu
hospit
persist
convuls
cerebrospin
tap
perform
nasopharyng
swab
rectal
swab
taken
bacteri
viral
cultur
antibiot
therapi
chang
amoxycillin
mgkgday
ceftazidim
mgkgday
aciclovir
mgkgday
suspicion
meningoenceph
cerebrospin
fluid
reveal
leukocytesml
normal
protein
normal
glucos
level
e
lectroencephalog
ram
show
abnorm
tempor
activ
bacteri
viral
cultur
neg
unfortun
cerebrospin
fluid
csf
viral
diagnost
three
day
later
serum
sampl
spinal
tap
taken
viral
diagnost
polymeras
chain
reaction
pcr
serum
csf
posit
herp
simplex
viru
hsv
despit
continu
aciclovir
die
day
viral
cultur
brain
lung
liver
spleen
throat
remain
neg
pcr
brain
liver
serum
throat
swab
posit
hsv
thu
confirm
diagnosi
herp
neonatorum
conclus
prompt
treatment
aciclovir
suspicion
herp
neonatorum
may
hamper
diagnosi
use
convent
viru
cultur
pcr
import
diagnost
tool
herp
neonatorum
influenza
b
viru
human
pathogen
whose
origin
possibl
reservoir
natur
known
influenza
b
viru
isol
natur
infect
harbor
seal
phoca
found
infecti
seal
kidney
cell
vitro
sequenc
analys
serolog
indic
influenza
viru
close
relat
strain
circul
human
year
earlier
retrospect
analys
sera
collect
seal
show
preval
antibodi
influenza
b
viru
percent
anim
none
anim
reservoir
harbor
influenza
b
virus
circul
past
may
pose
direct
threat
human
rabi
paulpierr
pastoret
bernard
brochier
univers
faculti
veterinari
medicin
immulogievaccinologi
boulevard
de
colonst
b
belgium
pasteur
institut
brussel
belgium
rabi
known
centuri
diseas
human
domest
wild
anim
mani
year
rabi
viru
thought
uniqu
exist
sever
distinct
rabiesrel
virus
recogn
special
interest
recent
lyssaviru
isol
bat
fruit
bat
fli
fox
presenc
pseudogen
g
l
cistron
impli
rabi
viru
evolutionarili
intermedi
rhabdovirida
famili
apart
gene
order
similar
vesiculoviru
genu
glycoprotein
alon
elicit
protect
immun
shown
use
vaccinia
viru
recombin
contain
rabi
europ
north
america
emphasi
nowaday
place
vaccin
wildlif
rabi
reservoir
control
rabi
start
wildlif
red
fox
vulp
vaccin
oral
rout
use
bait
efficaci
oral
administ
recombin
vacciniarabi
viru
vaccin
stabl
environ
perfectli
safe
target
non
target
anim
extens
use
continent
europ
belgium
franc
grandduchi
luxembourg
togeth
attenu
strain
rabi
viru
fox
vaccin
rabi
provok
dramat
decreas
rabi
incid
wild
domest
anim
consequ
similar
decreas
postexposur
treatment
human
elimin
rabi
larg
area
continent
europ
contribut
chang
quarantin
regul
rabi
unit
kingdom
therefor
improv
free
movement
pet
within
european
union
menangl
viru
member
famili
paramyxovirida
isol
stillborn
piglet
australia
affect
piggeri
experienc
reproduct
diseas
stillborn
piglet
frequent
skeleta
deform
degener
brain
spinal
cord
inclus
bodi
observ
neuron
viru
produc
vacuol
syncytia
focal
lysi
cultur
cell
nonhaemagglutin
appear
member
genu
rubulaviru
neutralis
antibodi
menangl
viru
detect
sera
sow
produc
affect
litter
well
high
proport
pig
affect
piggeri
two
associ
piggeri
antibodi
detect
sampl
collect
prior
onset
reproduct
diseas
neutralis
antibodi
also
detect
sera
two
human
piggeri
worker
expos
infect
pig
sera
three
speci
fruit
bat
pteropu
spp
australia
coloni
greyhead
fruit
bat
p
poliocephalu
roost
near
affect
piggeri
summer
thought
sourc
infect
pig
menangl
viru
erad
three
infect
piggeri
evid
infect
piggeri
australia
two
hantavirus
puumala
puu
dobrava
dob
seen
caus
human
diseas
europ
accord
reliabl
type
method
focusreduct
neutral
assay
use
appropri
hantaviru
serotyp
rtpcr
subsequ
sequenc
addit
tula
viru
infect
man
associ
human
diseas
phylogen
tree
show
ancient
cospeci
rodent
host
geograph
cluster
individu
hantaviru
strain
found
differ
part
europ
present
develop
sensit
specif
igm
igg
ela
base
baculovirusexpress
puu
dob
htn
nucleocapsid
n
protein
data
suggest
baculovirusexpress
n
antigen
indistinguish
nativ
protein
whole
n
protein
sensit
truncat
ntermin
antigen
studi
protein
express
alphaviru
express
system
earli
igg
respons
toward
n
protein
igg
antibodi
glycoprotein
detect
usual
convalesc
furthermor
although
first
day
diseas
igm
often
igg
antibodi
n
present
rare
case
puu
igm
antibodi
may
neg
day
onset
ill
pointof
care
diagnost
sensit
rapid
minut
immunochromatographi
test
detect
puu
igm
antibodi
base
baculovirusexpress
puu
n
develop
detect
puu
infect
finland
result
incid
hyperendem
region
b
mortal
howev
altogeth
case
diagnos
women
contract
diseas
mean
men
year
male
femal
ratio
puu
antibodi
preval
women
enter
matern
clinic
nationwid
whole
popul
endem
area
comparison
incid
preval
data
suggest
approxim
puu
infect
diagnos
background
hantavirus
hv
member
famili
bunyavirida
known
caus
varieti
diseas
haemorrhag
fever
renal
syndrom
hfr
pulmonari
syndrom
sever
serotyp
describ
least
five
pathogen
human
serotyp
differ
anim
reservoir
geograph
distribut
acut
phase
diseas
clinic
diagnosi
may
confirm
serolog
pcr
evalu
two
commerci
avail
immunoassay
use
sera
hv
suspect
nonhv
patient
enzym
immunoassay
eia
develop
mrl
diagnost
detect
immunoglobulin
igm
g
igg
sever
hv
serotyp
indirect
immunofluoresc
assay
ifa
progen
base
slide
coat
hantaan
viru
hntv
puumala
viru
puuv
infect
cell
studi
design
total
serum
sampl
use
studi
serum
panel
includ
serum
sampl
patient
suspect
mild
n
sever
n
hfr
patient
viral
infect
result
agreement
mrl
eia
progen
ifa
detect
igm
igg
serum
antibodi
rang
respect
nonhv
group
one
sampl
posit
progen
hntv
igm
ifa
none
progen
puuv
ifa
two
sampl
mrl
igm
eia
result
specif
respect
sensit
specif
mrl
ela
compar
progen
overal
puuv
hntv
ifa
igm
respect
igg
immunoassay
conclus
mrl
eia
prove
sensit
specif
assay
serolog
diagnosi
mild
sever
hfr
fold
protein
synthes
endoplasm
reticulum
er
live
cell
depend
assist
molecular
chaperon
factor
present
er
lumen
interact
erresid
protein
begin
alreadi
grow
nascent
chain
enter
er
lumen
translocon
complex
continu
matur
protein
readi
leav
er
commonli
observ
associ
involv
bip
major
homologu
er
two
lectinlik
chaperon
calnexin
cnx
calreticulin
crt
member
thiol
oxidoreductas
superfamili
protein
disulfid
isomeras
pdi
togeth
glucosidas
ii
udpglucos
glycoprotein
glucosyltransferas
promot
proper
fold
prevent
prematur
oligomer
inhibit
degrad
support
qualiti
control
newli
synthes
protein
er
differ
protein
analyz
becom
evid
interact
first
bip
cnx
bind
cnx
crt
associ
bip
other
sequenti
assist
bip
format
intramolecular
disulfid
bond
case
catalyz
pdi
case
oxidoreductas
act
togeth
result
indic
understand
molecular
basi
differenti
chaperon
select
import
analyz
grow
nascent
chain
live
cell
consid
kinet
elong
precis
time
cotransl
modif
signal
peptid
cleavag
nlink
glycosyl
oligosaccharid
trim
analyz
earli
event
fold
semliki
forest
viru
el
glycoprotein
influenza
hemagglutinin
found
alreadi
cotransl
transloc
glycoprotein
choic
made
distinct
chaperon
system
one
compris
bip
possibl
pdi
cnx
crt
select
chaperon
depend
locat
nlink
glycan
grow
nascent
chain
chaperon
compet
bind
site
incom
polypeptid
whichev
bind
first
domin
earli
stage
coand
posttransl
fold
associ
nascent
chain
fulllength
glycoprotein
delay
prevent
bind
chaperon
later
fold
process
transfer
one
pathway
may
howev
take
place
cours
need
electron
microscopi
cr
madeley
newcastleupontyn
uk
peopl
recognis
friend
appear
rather
voic
footfal
even
cloth
virus
though
mani
diagnost
techniqu
detect
either
trace
rather
viru
particl
classifi
viru
decid
final
seen
look
like
viru
ever
misclassifi
morpholog
alon
fact
underlin
ivtc
clearli
need
provid
electron
microscop
visualis
virus
within
countri
provid
comprehens
diagnost
servic
identifi
virus
may
invad
circul
within
border
present
trend
restrict
avail
electron
microscop
em
central
refer
laboratori
remot
frontlin
diagnost
virolog
dire
recognit
varieti
virus
diagnost
materi
skill
taken
put
willit
need
regular
practic
nurtur
microscopist
need
daili
challeng
look
virion
diagnost
prepar
know
specimen
contain
even
contain
anyth
standard
prepar
provid
challeng
regular
comprehens
work
though
bring
sideeffect
test
becom
cheaper
usedth
major
expens
provid
instrument
microscopist
run
expens
trivial
reason
novelti
scienc
diagnost
em
serious
threatw
blame
lose
fail
argu
strongli
enough
retain
unlik
diagnost
techniqu
infecti
diseas
em
undirect
open
view
direct
rapid
catchal
method
detect
even
agent
previous
consid
involv
neg
stain
follow
simpl
rapid
protocol
particl
size
shape
specif
fine
structur
assess
criteria
help
assign
observ
virion
one
animalspecif
viru
famili
rapid
morpholog
diagnosi
advantag
case
fulli
suffici
clinician
guid
patient
treatment
order
keep
certain
diagnost
standard
em
diagnosi
regular
extern
qualiti
control
measur
essenti
henc
start
extern
qualiti
assess
program
em
viral
diagnosi
eqaemv
compris
two
eqa
run
per
year
present
particip
countri
regist
mainli
european
countri
inform
eqa
program
workshop
laboratori
cours
obtain
world
wide
web
http
wwwelectronmicroscopyorg
effect
need
program
becom
obviou
look
still
increas
number
particip
laboratori
countri
well
increas
rate
correct
diagnost
result
provid
modern
enrich
techniqu
regular
eqa
measur
implement
em
also
futur
play
use
competit
role
within
convent
moleculargenet
diagnost
armament
link
prophylact
therapeut
intervent
molecular
evolut
virus
ls
christensen
depart
clinic
microbiolog
rigshospitalet
copenhagen
denmark
vaccin
program
therapeut
intervent
involv
contamin
blood
product
potenti
significantli
affect
evolut
virus
studi
evolut
affect
measur
turn
might
significantli
contribut
understand
drive
forc
mechan
evolut
studi
anim
herpesvirus
review
reveal
clonal
popul
structur
global
circul
strain
one
hand
andon
handcambrian
explosionlik
event
take
place
daytoday
evolut
viru
due
coinfect
explos
event
shown
take
place
result
use
live
vaccin
involv
transit
stage
fit
peak
jump
characteris
extrem
inher
divers
viru
strain
question
address
cambrian
explosionlik
event
might
explain
evolutionari
pattern
parvoviru
measl
viru
addit
need
perspect
establish
european
network
studi
molecular
epidemiolog
evolut
discuss
context
two
decad
diagnost
virolog
unit
turku
use
antigen
detect
method
surveil
rsv
infect
finland
sinc
method
essenti
timeresolv
fluoroimmunoassay
trfia
monoclon
antibodi
diagnost
servic
back
cultur
serolog
allow
occasion
evalu
immunoassay
perform
past
twenti
year
rsv
epidem
season
finland
occur
twoyear
cycl
start
everi
second
year
minor
spring
outbreak
follow
major
one
next
winter
season
rsv
circul
month
monoclon
antibodi
differenti
b
strain
group
use
type
clinic
specimen
isol
group
b
strain
predomin
altern
cycl
except
preval
group
b
strain
lower
expect
neither
strain
group
predomin
result
genotyp
limit
nucleotid
sequenc
g
protein
gene
group
strain
implic
emerg
group
genotyp
rare
previou
year
clinic
studi
perform
turku
univers
hospit
rsv
infect
group
strain
found
sever
group
b
strain
wherea
latter
often
associ
acut
otiti
media
although
hospitalis
case
laboratori
verifi
reinfect
rare
find
suggest
agedepend
strain
groupspecif
protect
twoyear
cyclic
pattern
rsv
infect
seem
manifest
race
herd
immun
viru
variat
molecular
epidemiolog
measl
viru
learn
monitor
vaccin
strategi
claud
p
muller
frank
hans
mick
mulder
anh
truong
collabor
center
measl
laboratoir
nation
de
po
box
luxembourg
sequenc
wildtyp
isol
prove
effect
tool
monitor
measl
circul
confirm
epidemiolog
link
case
unit
state
molecular
epidemiolog
demonstr
interrupt
viru
transmiss
europ
measl
incid
remain
high
part
diseas
like
still
endem
due
insuffici
vaccin
luxembourg
experienc
outbreak
least
case
case
continu
report
throughout
suggest
sustain
viru
transmiss
use
molecular
epidemiolog
investig
appar
endem
basi
n
gene
sequenc
isol
assign
typic
european
genotyp
sequenc
divers
within
tempor
spatial
confin
outbreak
cterminu
far
lower
divers
within
two
cocircul
cluster
endem
virus
observ
nigeria
nucleotid
distanc
outbreak
isol
least
three
four
time
higher
suggest
independ
origin
latter
virus
similarli
four
virus
found
luxembourg
thought
least
two
three
origin
thu
use
intraoutbreak
divers
measur
abl
differenti
sporad
infect
caus
endem
viru
strain
pseudooutbreak
due
multipl
unrel
import
case
approach
describ
may
also
use
monitor
effect
mass
campaign
measl
report
incomplet
commun
highli
mobil
case
mani
develop
countri
aberr
genotyp
reveal
recombin
hepat
b
viru
strain
vietnam
charl
hannoun
norder
magnu
lindh
depart
clinic
virolog
teborg
univers
teborg
sweden
depart
virolog
swedish
institut
infecti
diseas
control
stockholm
sweden
seven
genotyp
hepat
b
viru
hbv
describ
rel
complet
genom
east
asia
world
hbv
carrier
live
studi
five
complet
hbv
genom
vietnames
origin
studi
genotyp
produc
atyp
pattern
hbsag
sequenc
marker
serotyp
adw
phylogenet
tree
analysi
two
genom
cluster
genotyp
c
three
separ
branch
genotyp
b
c
similar
plot
bootscan
analysi
strain
show
sign
recombin
phylogenet
tree
analysi
two
segment
separ
support
recombin
genotyp
c
put
new
genotyp
possibl
subgroup
genotyp
one
segment
nt
genotyp
c
origin
major
part
genom
nt
place
branch
near
genotyp
find
encourag
studi
genotyp
recombin
hbv
geograph
region
molecular
clock
analysi
three
major
lineag
primat
tcell
lymphotrop
virus
sonia
van
dooren
marco
salemi
annemiek
vandamm
rega
institut
medic
research
minderbroedsstraat
leuven
belgium
molecular
clock
hypothesi
test
statist
evalu
full
genom
align
sequenc
three
major
lineag
primat
tlymphotrop
virus
ptlv
stlvl
first
second
codon
posit
code
region
use
analys
show
differ
ptlv
lineag
evolv
differ
rate
howev
clock
hypothesi
reject
stlvl
htlvistlvi
consid
third
codon
posit
anthropolog
document
migrat
ptlv
host
correl
ptlv
diverg
time
estim
evolutionari
time
scale
ptiv
accord
calcul
famili
virus
origin
one
million
year
ago
also
estim
separ
pygmi
chimpanze
much
earlier
year
ago
thu
human
simian
lineag
primat
tlymphotrop
virus
probabl
aros
speciat
host
ancient
interspeci
transmiss
final
molecular
clock
analysi
show
two
differ
evolutionari
rate
viru
seem
evolv
time
faster
inject
drug
user
idu
endem
infect
tribe
dramat
increas
rate
evolut
among
idu
accord
analys
occur
last
one
hundr
year
might
import
consequ
futur
pathogen
viru
effect
ignor
recombin
phylogenet
analys
mikkel
h
schierup
jotun
hein
depart
ecolog
genet
univers
aarhu
aarhu
denmark
recombin
appear
common
popul
survey
hiv
virus
time
phylogenet
tree
reconstruct
data
set
use
evolutionari
infer
recombin
occur
differ
part
sequenc
differ
histori
singl
phylogenet
tree
exist
quantifi
amount
recombin
need
phylogenet
tree
affect
simul
sequenc
recombin
infer
phylogenet
tree
ignor
recombin
found
even
small
amount
recombin
caus
molecular
clock
disappear
thu
question
date
event
viru
phylogeni
furthermor
larg
amount
rate
heterogen
infer
virus
may
artefact
ignor
recombin
final
ignor
recombin
make
tree
appear
starshap
may
taken
evid
exponenti
growth
rather
recombin
develop
antihiv
lipopeptid
vaccin
use
sever
hivspecif
extent
larg
peptid
ad
lipid
group
mixtur
six
lipopeptid
deriv
regulatori
structur
protein
nef
gag
env
prepar
phase
studi
conduct
evalu
immunogen
toler
vaccin
hivseroneg
volunt
three
inject
fourth
inject
lipopeptid
vaccin
given
volunt
follow
booster
effect
final
evalu
long
last
immun
respons
period
year
show
first
time
lipopeptid
vaccin
contain
differ
epitop
character
nef
gag
env
viral
protein
abl
induc
strong
multiepitop
b
cell
respons
human
alreadi
three
inject
et
al
j
virol
vaccin
subject
produc
specif
igg
antibodi
recogn
nef
gag
protein
helper
cell
respons
well
specif
cytotox
cell
also
obtain
cell
abl
recogn
natur
process
viral
protein
moreov
hivspecif
ifngamma
secret
cell
detect
exvivo
confirm
one
stimul
band
tcell
respons
extens
boost
fourth
inject
final
long
last
polyepitop
cell
respons
sustain
period
year
conclud
believ
develop
antihiv
lipopeptid
vaccin
suitabl
method
induc
b
cell
multiepitop
respons
human
ttir
institut
virolog
univers
iceland
il
po
box
iceland
one
twin
lamb
eight
pair
twin
immun
formalin
inactiv
whole
visna
viru
strain
k
alun
ad
vaccine
develop
antibodi
major
protein
viru
shown
western
blot
neutral
antibodi
ann
ny
acad
sci
vol
vaccin
twin
hous
five
heavili
infect
sheep
close
sheep
hut
year
later
five
unvaccin
twin
seroconvert
five
twin
pair
slaughter
tissu
sampl
spleen
hilar
lymph
node
lung
chorioid
plexus
collect
viru
cultiv
viru
grown
five
unvaccin
twin
two
vaccine
three
vaccine
neg
although
everi
drop
tissu
cultur
fluid
explant
cocultur
organ
pass
month
although
small
number
anim
experi
result
seem
indic
possibl
vaccin
slow
lentiviru
infect
convent
prepar
inactiv
vaccin
effect
amount
cellular
locat
stabil
antigen
capac
induc
cytotox
cell
respons
ank
huckried
barryle
waart
marijk
holtrop
derkjan
de
groot
jan
wilschut
molecular
virolog
univers
groningen
deusinglaan
groningen
av
netherland
activ
cytotox
lymphocyt
ctl
requir
present
antigen
peptid
mhc
class
l
molecul
antigenpres
cell
peptid
present
gener
proteasom
degrad
antigen
present
cytosol
subsequ
transport
via
tap
transport
er
associ
nascent
mhc
class
l
molecul
thu
load
mhc
class
l
complex
transport
via
golgi
apparatu
plasma
membran
attempt
induc
ctl
respons
vaccin
effici
present
antigen
question
import
use
influenza
nucleoprotein
np
model
antigen
therefor
investig
effect
amount
locat
stabil
antigen
present
mhc
class
l
molecul
abil
prime
specif
ctl
vivo
immun
perform
use
recombin
semliki
forest
viru
sfv
particl
encod
np
transfect
recombin
sfv
lead
high
express
transgen
h
whereaft
transfect
cell
die
apoptosi
four
differ
construct
prepar
sfvnp
fulllength
np
sfvenhnp
np
clone
behind
translat
enhanc
sequenc
deriv
sfv
capsid
protein
sequenc
sfvnlsnp
np
miss
first
amino
acid
includ
nuclear
localis
signal
nl
sfvubnp
np
ubiquitin
monom
fuse
nterminu
histochem
examin
transfect
cell
demonstr
np
locat
nucleu
ubnp
found
mainli
nucleu
also
cytoplasm
nlsnp
detect
exclus
cytoplasm
indic
first
amino
acid
inde
essenti
transport
np
nucleu
biochem
analysi
transfect
cell
show
construct
express
substanti
level
expect
express
enhnp
higher
construct
pulsechas
experi
reveal
np
enhnp
stabl
estim
halflif
h
despit
cytoplasm
local
thu
excel
access
proteasom
degrad
nlsnp
show
half
life
two
construct
contrast
ubnp
target
directli
proteasom
via
ubiquitin
moieti
appear
degrad
much
faster
use
differ
construct
immunis
mice
current
investig
whether
extent
immun
respons
term
frequenc
activ
ctl
precursor
determin
predominantli
amount
antigen
degrad
kinet
inchausp
boucreux
c
brinster
fournilli
n
renard
vidalin
inserm
u
lyon
franc
studi
natur
infect
hepat
c
viru
hcv
remain
incomplet
increas
evid
support
concept
humor
cellular
immun
respons
play
role
control
possibl
prevent
infect
respons
except
appar
minor
case
gener
incompet
elimin
viru
infect
host
success
vaccin
simpli
mimic
respons
found
natur
infect
rather
induc
optim
vigour
one
explor
differ
way
formul
hcv
vaccinedna
order
reach
goal
plasmid
engin
express
differ
form
glycoprotein
el
particular
form
keep
abil
interact
produc
noncoval
dimer
presum
exist
surfac
viral
particl
addit
studi
address
issu
role
play
sugar
immunogen
glycoprotein
differ
dnaexpress
vector
well
molecular
target
strategi
also
employ
evalu
capac
hcvimmunogen
induc
either
humor
cellular
immun
data
gather
balbc
mice
mice
transgen
human
hla
well
limit
instanc
small
primat
develop
safe
vector
base
transcomplement
defect
tgev
packag
cell
line
javier
ortego
sola
escor
h
laudet
l
enjuan
centro
nacion
de
csic
depart
molecular
cell
biolog
campu
universidad
noma
madrid
spain
inra
unit
de
virologi
immunologi
moleculair
franc
tgev
fulllength
infecti
cdna
gener
laboratori
cdna
use
develop
safe
vector
vaccin
gene
therapi
base
transcomplement
packag
cell
line
defect
tgev
genom
express
heterolog
gene
packag
cell
line
stabli
express
individu
tgev
structur
protein
e
n
establish
use
noncytopath
sindbi
viru
replicon
express
vector
frolov
et
al
cell
line
gener
transfect
construct
cell
constitut
express
porcin
aminopeptidasen
major
receptor
tgev
delma
b
et
al
express
tgev
protein
detect
western
blot
immunocitochemistri
could
maintain
least
ten
passag
cell
cultur
presenc
sindbi
viru
replicon
interfer
product
infect
tgev
viral
particl
cell
line
assess
viru
titrat
pfuml
knockedout
tgev
genom
gener
cdna
order
produc
defect
viral
particl
complement
tran
packag
cell
line
increas
clone
capac
tgev
deriv
vector
nonessenti
gene
tgev
delet
modifi
cdna
produc
infecti
viru
titer
compar
wild
type
tgev
cdna
green
fluoresc
protein
gfp
gene
introduc
defect
cdna
transcript
regulatori
sequenc
gene
lead
high
gfp
express
level
gener
tgev
genom
defici
structur
gene
complement
packag
cell
line
gener
defect
viral
particl
develop
safe
vector
vaccin
develop
gene
therapi
discuss
highli
sensit
pcr
revers
hybrid
line
probe
assay
lipa
detect
identif
hpv
genotyp
bernhard
kleter
ac
molijn
lj
van
doorn
wgv
quint
delft
diagnost
laboratori
r
de
graafweg
delft
ad
netherland
adequ
detect
genotyp
hpv
dna
requir
assess
role
hpv
infect
cervic
patholog
aim
present
studi
evalu
recent
develop
primer
set
revers
hybrid
assay
lipa
detect
identif
hpv
genotyp
method
evalu
larg
number
clinic
materi
permit
hpv
analysi
cervic
scrape
includ
thinprep
sampl
well
freshli
frozen
biopsi
specimen
primer
highli
sensit
detect
hpv
dna
women
normal
cytolog
approxim
ascu
case
case
mild
sever
dyskaryosi
patient
cervic
carcinoma
due
small
amplim
size
primer
also
detect
hpv
dna
formalinfix
paraffinembed
materi
archiv
pap
smear
lipa
result
compar
direct
sequenc
analysi
spf
amplim
typespecif
pcr
show
highli
concord
result
multipl
hpv
genotyp
frequent
detect
lipa
case
normal
cytolog
ascu
dyskaryot
case
carcinoma
sequenc
analysi
underestim
preval
multipl
genotyp
spfpcr
combin
hpvlipa
offer
highli
sensit
specif
tool
investig
hpv
infect
facilit
clinic
epidemiolog
studi
describ
two
mutliplex
assay
allow
detect
seven
commonest
virus
encount
patient
suspect
viral
mening
enceph
one
assay
detect
herp
simplex
viru
hsv
type
varicella
zoster
viru
vzv
human
herpesviru
type
human
enterovirus
second
detect
cytomegaloviru
cmv
epsteinbarr
viru
ebv
jc
viru
well
toxoplasma
gondii
follow
singl
round
multiplex
pcr
amplif
specif
identif
viral
protozoan
sequenc
achiev
revers
hybrid
specif
probe
lineprob
assay
lipa
multiplex
pcrlipa
system
found
capabl
detect
genom
equival
l
csf
evalu
use
extern
qualiti
assess
panel
hsv
enteroviru
cmv
upon
evalu
panel
csf
submit
diagnost
evalu
viru
identifi
sampl
gondii
identifi
one
sampl
virus
found
commonli
csf
show
leukocytosi
andor
elev
protein
level
interestingli
howev
none
eleven
patient
hsv
detect
csf
leukocytosi
wherea
seven
eight
patient
hsv
infect
leukocytosi
hsv
infect
frequent
associ
asept
mening
young
women
multipl
herpesvirus
commonli
detect
patient
hivrel
diseas
use
assay
could
thu
reduc
time
number
pcr
assay
requir
confirm
exclud
viral
diagnosi
patient
central
nervou
system
diseas
lipa
detect
format
also
achiev
reliabl
sensit
postpcr
viral
identif
realtim
pcr
detect
herp
virus
sampl
immunosupress
patient
susan
nicol
brass
ha
cubi
rcvl
citi
hospit
greenbank
drive
edinburgh
uk
purpos
herp
virus
import
caus
morbid
mortal
patient
immunocompromis
due
transplant
aid
treatment
avail
import
develop
rapid
screen
system
identifi
patient
risk
clinic
diseas
method
gene
vzv
gpd
gpg
mie
gb
gene
cmv
amplifi
use
nest
realtim
pcr
system
optimis
use
materi
obtain
cell
cultur
product
clone
pgemt
ascertain
sensit
system
dna
extract
clinic
sampl
use
pcr
system
unextract
sampl
also
test
result
compar
convent
serolog
cultur
sensit
vzv
bewteen
copi
cmv
copi
sensit
cmv
system
increas
carri
initi
cycl
pcr
use
outer
primer
ad
realtim
pcr
vzv
hsvi
cmv
posit
result
obtain
one
detect
cultur
spike
csf
sampl
detect
whether
extract
turnaround
time
less
hour
compar
mean
day
cultur
immunofluoresc
conclus
realtim
pcr
cost
effect
sensit
rapid
mean
detect
virus
need
extract
sampl
system
therefor
benefit
screen
immunocompromis
patient
diagnost
detect
quantif
pathogen
bunyavirida
taqmanrtpcr
approach
manfr
weidmann
ft
hufert
dept
virolog
inst
med
microbiolog
hygien
univers
freiburg
hermannherderstr
freiburg
germani
taqmanpcr
technolog
offer
possibl
specif
highli
sensit
one
tube
rtpcr
need
second
round
nest
pcr
includ
sequenc
avail
embldatabank
concept
pcrsystem
appli
devis
set
primer
detect
distinguish
pathogen
bunyavirida
genera
bunyaviru
hantaviru
nairoviru
phleboviru
modular
approach
hantavirus
first
set
primer
identifi
pathogen
virus
genera
level
simultan
signal
also
give
preliminari
indic
ident
put
speci
second
set
primer
entir
speci
specif
abl
identifi
pathogen
hantavirus
without
doubt
apart
pure
diagnost
valu
taqmanpcr
scheme
also
offer
possibl
monitor
diseas
develop
infect
patient
quantifi
viral
load
continuo
time
point
role
nest
polymeras
chain
reaction
detect
respiratori
pathogen
children
bronchiol
grace
ong
pv
coyl
de
wyatt
hj
oneil
c
mccaughey
region
viru
laboratori
royal
hospit
trust
grovesnor
road
belfast
northen
ireland
uk
purpos
influenza
respiratori
syncyti
viru
rsv
cocircul
winter
month
novemb
januari
nest
polymeras
chain
reaction
pcr
compar
immunofluoresc
detect
rsv
serotyp
b
children
suspect
bronchiol
coinfect
influenza
chlamydia
spp
enterovirusrhinoviru
also
investig
use
molecular
techniqu
method
total
nasopharyng
secret
collect
babi
admit
bronchiol
month
januari
compris
rsv
posit
n
rsv
neg
n
specimen
test
rsv
serotyp
influenza
chlamydia
spp
enterovirusrhinoviru
npcr
specimen
also
neg
influenza
influenza
b
adenoviru
parainfluenza
viru
type
result
twentysix
specimen
posit
rsv
method
two
secret
neg
rsv
posit
rsv
b
respect
npcr
rsv
rsv
b
influenza
detect
specimen
rsv
neg
npcr
chlamydia
spp
identifi
c
trachomati
present
one
infant
rsv
b
gave
recent
histori
treat
c
trachomati
conjunct
enteroviru
found
secret
rsv
influenza
rsv
rsv
detect
npcr
one
rsv
conclus
npcr
prove
sensit
specif
detect
rsv
influenza
presenc
influenza
infect
secret
report
neg
use
convent
techniqu
highlight
infect
control
issu
cohort
bronchiol
patient
hospit
demonstr
rsv
c
trachomati
infect
address
contribut
latter
bronchiol
efficaci
treatment
erad
chlamydia
carriag
child
differenti
enteroviru
genu
level
report
near
futur
lamivudin
potent
inhibitor
hepat
b
viru
replic
hepat
b
viru
resist
lamivudin
describ
patient
treatment
characterist
mutat
socal
ymdd
motif
combin
mutat
posit
polymeras
gene
appear
resist
usual
observ
increas
viral
hbv
dna
load
use
hybrid
assay
limit
detect
million
copi
per
ml
combin
sequenc
analysi
pcr
product
result
conclus
actuari
cumul
resist
incid
rotterdam
cohort
new
gener
assay
commerci
digen
hybrid
captur
inhous
develop
real
time
detect
assay
measur
accur
hbv
dna
larg
dynam
rang
develop
mutat
link
resist
lamivudin
monitor
use
innolipa
hbv
dr
resist
strip
enabl
semiquantit
detect
wildtyp
mutat
viral
sequenc
retrospect
analysi
analyz
occurr
lamivudin
resist
relat
chang
viral
load
increas
serum
transaminas
alt
eleven
patient
treat
mg
lamivudin
per
day
median
week
rang
week
median
viral
load
copi
per
ml
rang
patient
monitor
least
monthli
basi
reduct
viral
load
median
log
rang
log
alway
detect
real
time
detect
assay
time
start
therapi
appear
first
mutat
detect
innolipa
hbv
dr
week
rang
increas
viral
load
detect
week
rang
patient
mixtur
yidd
yvdd
variant
observ
given
timepoint
reduct
alt
observ
patient
averag
rang
increas
alt
observ
week
rang
averag
week
later
appear
mutat
link
resist
conclus
combin
accur
hbv
dna
measur
innolipa
hbv
dr
resist
assay
identifi
hbv
lamivudin
resist
strain
earliest
timepoint
elev
alt
level
use
clinic
patient
manag
implement
surveil
network
herp
simplex
viru
resist
antivir
drug
bruno
lina
thouvenot
c
danv
f
morfin
boucher
berlin
aymard
laboratori
virolog
anneci
bordeaux
brest
clermontferrand
grenobl
marseil
montpelli
nanci
nant
pari
poitier
saintetienn
toulous
armi
pari
laboratoir
de
virologi
domain
rockfel
avenu
rockefel
lyon
cedex
franc
laboratoir
glaxowellcom
rout
de
versail
marlyleroi
franc
background
continu
increas
acyclovir
acv
consumpt
could
rise
preval
herp
simplex
viru
hsv
acvresist
establish
glaxowellcom
laboratori
collabor
pilot
network
hospit
laboratori
virolog
evalu
preval
acvresist
method
sampl
collect
immunocompet
immunocompromis
patient
herp
simplex
virus
isol
vero
cell
identifi
immunofluoresc
test
type
sent
lyon
hsv
acvsuscept
test
use
simpl
colorimetr
assay
micropl
hsv
isol
dose
test
acv
read
day
incub
od
nm
result
overal
hsv
isol
collect
patient
twentyseven
patient
excret
acvresist
hsv
percentag
rang
immunocompet
immunocompromis
patient
haemopathi
organ
transplant
hiv
infect
bone
marrow
transplant
among
immunocompromis
patient
excret
acvresist
hsv
previous
receiv
acv
treatment
exhibit
clinic
resist
immunocompromis
patient
excret
acvsensit
hsv
previous
receiv
acv
treatment
exhibit
clinic
resist
conclus
acvresist
preval
seem
increas
howev
remain
major
concern
manag
hsv
infect
identif
mutat
associ
resist
bay
novel
nonnucleosid
inhibitor
cytomegaloviru
replic
iri
bueger
human
cytomegaloviru
hcmv
betaherpesviru
caus
sightand
lifethreaten
diseas
immunocompromis
patient
treatment
current
market
antihcmv
drug
associ
poor
oral
bioavail
doselimit
toxic
clinic
develop
compound
bay
member
new
class
nonnucleosid
drug
reveal
inhibit
late
stage
replic
cycl
cmv
kinet
studi
order
identifi
viral
target
resist
strain
hcmv
mcmv
gener
vitro
select
increas
inhibitor
concentr
sequenc
analysi
resist
hcmv
strain
resist
mcmv
smith
map
mutat
orf
protein
thought
essenti
viral
dna
cleavag
packag
genom
procapsid
mutat
result
experiment
confirm
function
dna
cleavag
assay
includ
southern
blot
techniqu
case
wildtyp
mcmv
cleavag
viral
dna
genom
terminu
correl
differ
dose
inhibitor
viral
dna
cleavag
resist
mcmv
unaffect
recombin
mcmv
mutant
gener
cotransfect
mous
embryo
fibroblast
combinatori
set
overlap
mcmv
dna
fragment
drug
suscept
profil
reconstitut
viru
popul
determin
use
quantit
laczbas
enzym
assay
role
mutat
develop
mcmv
resist
bay
present
find
strongli
suggest
bay
specif
inhibit
cleavag
highmolecularweight
viral
dna
concatem
monomer
genom
length
perform
uniqu
mechan
action
distinct
market
dna
replic
inhibitor
preval
pattern
antiretrovir
resist
patient
recent
infect
anna
maria
geretti
smith
donati
p
easterbrook
background
high
preval
drugresist
hiv
report
patient
north
america
data
european
patient
remain
limit
examin
distribut
subtyp
preval
antiretrovir
resist
patient
infect
januari
method
patient
present
seroconvers
interv
b
month
first
posit
last
neg
hiv
test
caucasian
homosexu
male
caribbean
african
patient
femal
male
heterosexu
acquir
infect
viral
rna
plasma
collect
diagnosi
analys
direct
sequenc
rt
proteas
gene
subtyp
determin
sequenc
analysi
peptideeia
result
nonb
subtyp
intersubtyp
recombin
found
patient
zdv
primari
resist
mutat
found
one
homosexu
caucasian
patient
patient
also
carri
secondari
mutat
rt
proteas
two
rt
mutat
persist
month
patient
receiv
ddl
nevirapin
mutat
disappear
time
secondari
mutat
detect
rt
gene
patient
proteas
gene
patient
conclus
heterogen
south
london
cohort
found
high
preval
nonb
subtyp
intersubtyp
recombin
remain
low
rate
transmiss
primari
resist
mutat
mutat
howev
persist
absenc
zdv
pressur
analysi
expand
cohort
ongo
genotyp
phenotyp
resist
test
pcr
neg
patient
haart
ann
spielhofen
b
schel
j
cinatl
jr
hw
doerr
institut
medic
virolog
johann
wolfgang
goetheunivers
frankfurtmain
paulehrlich
str
frankfurt
germani
introduct
highli
activ
antiretrovir
therapi
haart
made
possibl
lower
viral
load
vl
infect
patient
detect
level
commerci
test
kit
ie
rna
copml
despit
haart
howev
still
possibl
erad
viru
complet
rest
latent
infect
memori
tcell
reach
therapi
aim
studi
determin
whether
singl
clone
latent
infect
memori
cell
obtain
patient
undetect
viral
load
differ
resist
pattern
occurr
syncytiuminduc
si
nonsi
nsi
strain
method
pbmc
hivposit
donor
deplet
separ
cultiv
microtitr
plate
immobilis
anti
antibodi
six
respond
test
maintain
vl
b
rna
copml
haart
one
year
hiv
strain
cultiv
frequenc
per
cell
resist
genotyp
analys
revers
transcriptas
proteas
gene
sequenc
phenotyp
cultur
phapbmc
presenc
antiretrovir
drug
sl
nsi
phenotyp
determin
use
assay
system
result
four
patient
drugsensit
drugresist
strain
could
detect
two
patient
develop
drug
resist
within
viral
genom
four
patient
show
sl
nsi
strain
two
patient
nsi
strain
echoviru
member
human
enterovirusb
speci
famili
picornavirida
common
caus
epidem
asept
mening
show
strikingli
monotyp
pattern
molecular
evolut
overal
genet
diverg
capsid
code
region
genom
independ
field
isol
clearli
less
previous
studi
enterovirus
sever
independ
genet
lineag
design
genotyp
within
enteroviru
serotyp
typic
cocircul
singl
genotyp
appear
almost
exclus
preval
last
two
decad
europ
northern
america
within
genotyp
strain
isol
late
late
cluster
separ
strain
caus
widespread
epidem
differ
part
europ
second
half
close
relat
spite
limit
rang
genet
variat
rang
amino
acid
sequenc
differ
analys
strain
almost
doubl
compar
coxsackieviru
strain
show
wider
genet
diverg
variabl
amino
acid
posit
cluster
region
known
antigen
enterovirus
possibl
antigen
select
play
role
evolut
far
data
support
hypothesi
aim
studi
develop
rapid
highli
sensit
molecular
tool
capabl
identifi
rabi
viru
isol
zoonot
anim
event
rabi
outbreak
rabi
rabiesrel
virus
classifi
six
distinct
genotyp
propos
seventh
genotyp
recent
report
australia
rabi
virus
form
multipl
biotyp
within
genotyp
mani
biotyp
identifi
use
monoclon
antibodi
reactiv
pattern
highresolut
differenti
recent
becom
possibl
applic
genet
sequenc
specif
gene
region
current
sequenc
variabl
part
n
gene
encod
rabi
viru
nucleoprotein
viru
isol
obtain
around
world
molecular
studi
demonstr
genet
distinct
group
virus
within
genotyp
relat
host
speci
geograph
distribut
result
databas
viru
sequenc
potenti
form
import
epidemiolog
tool
could
contribut
global
diseas
control
rabi
use
hbv
surfac
antigen
variabl
confirm
migrat
pattern
pacif
peopl
ashraf
basuni
lesleyann
butterworth
graham
cooksley
stephen
locarnini
william
f
evid
histori
mitochondri
dna
sequenc
peopl
south
east
asia
migrat
either
eastward
micronesia
southward
indonesia
melanesia
polynesia
hbv
classifi
seven
genotyp
g
genotyp
wide
distribut
old
world
genotyp
b
c
confin
east
asia
genotyp
e
mainli
found
subsaharan
africa
genotyp
f
aborigin
popul
america
recent
discov
g
usa
franc
nine
subtyp
one
subtyp
found
within
genotyp
studi
hbv
surfac
antigen
hbsag
variat
four
differ
island
group
kiribati
micronesia
vanuatu
fiji
tonga
three
melanesiapolynesia
list
west
east
rel
se
asia
sampl
collect
unvaccin
children
adult
number
villag
island
test
hbsag
hbsag
posit
amplifi
pcr
sequenc
predomin
sequenc
kiribati
genotyp
subtyp
differ
melanesia
polynesia
genotyp
c
adrq
howev
substanti
proport
fiji
impli
mix
popul
interchang
centuri
keep
hypothesis
migrat
west
east
vanuatu
fiji
tonga
specif
variant
identifi
island
either
increas
decreas
west
east
case
variant
found
sampl
vanuatu
yet
occur
major
person
tonga
vice
versa
addit
linkag
two
amino
acid
found
specif
island
conclud
popul
wave
carri
specif
subtyp
howev
preval
rate
vari
significantli
order
investig
preval
ttv
two
geograph
distant
countri
test
total
serum
sampl
german
blood
donor
n
pregnant
women
n
well
sera
ghanes
individu
seminest
polymeras
chain
reaction
assess
genet
divers
ttv
genom
detail
partial
nucleotid
sequenc
analysi
within
perform
long
fragment
sequenc
compar
repres
known
genotyp
twenti
individu
germani
ghana
found
pcrposit
indic
ttv
infect
common
respect
endem
area
studi
phylogenet
analysi
reveal
one
sampl
belong
genotyp
alreadi
recogn
among
human
howev
differ
distribut
four
five
german
sampl
group
univers
genotyp
genotyp
found
countri
examin
one
genotyp
ghanes
sampl
group
genotyp
interest
nucleotid
amino
acid
homolog
one
sampl
ghana
sequenc
known
genotyp
low
respect
indic
identif
new
variant
repres
genotyp
report
investig
interspeci
transmiss
phylogenet
analyz
ltr
env
sequenc
htlvi
stlvi
strain
least
four
five
african
htlvi
subtyp
cluster
stlvi
strain
accord
geograph
origin
rather
host
speci
pan
troglodyt
seem
simian
reservoir
mandrillu
sphinx
strain
seem
origin
htlvid
htlvif
subtyp
htlvle
cluster
cercopithecu
papio
spp
strain
howev
simian
counterpart
far
melanesian
htlvic
relat
indonesian
stlvi
strain
seem
brought
melanesia
australia
along
first
human
settler
date
origin
african
clade
perform
molecular
clock
analysi
combin
ltrenv
third
codon
posit
sequenc
molecular
clock
hold
use
start
date
anthropolog
document
migrat
melanesian
settler
indonesia
melanesia
australia
year
ago
estim
viru
spread
africa
around
year
ago
differ
african
htlvi
subtyp
aros
ya
although
less
ya
interspeci
transmiss
must
occur
time
period
probabl
still
ongo
drive
forc
african
ptlvi
evolut
studi
use
ml
tree
env
gene
reconstruct
ancestr
state
charact
calcul
synonymousnonsynonym
substitut
ratio
provid
evid
strong
neg
select
pressur
support
purifi
select
irrespect
intraor
interspeci
transmiss
